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Stem cell transplants (SCTs) are complicated treatments utilized to treat hematologic 
malignancies and other disorders, such as multiple myeloma, non-Hodgkin’s lymphoma, 
Hodgkin’s lymphoma, acute myeloid leukemia, neuroblastomas, germ cell tumors, amyloidosis, 
and autoimmune disorders such as systemic lupus erythematosus and systemic sclerosis.  The 
complex care of patients undergoing SCTs place them at high risk for adverse outcomes, 
including infection, cytomegalovirus, graft vs host disease, secondary new cancers, infertility, 
and sexual dysfunction (American Cancer Society, 2020).  Survivorship care plans (SCPs) are a 
vital part of the discharge process to educate allogenic SCT patients about post-transplantation 
care.  SCPs are implemented to reduce the risk of common complications and hospital re-
admissions in post-SCT patients.  The purpose of this project is to use SCPs to reduce 30-day re-
admission rates of allogenic SCT patients.  A review of literature was conducted to analyze the 
impact of SCPs on post-transplantation knowledge of preventative measures and common 
complications. The SCP Questionnaire was created to measure knowledge received from the 
SCP to highlight the effectiveness of preventative measures and common complications post-
transplantation.  Kurt Lewin’s Change Theory provided the underlying theoretical framework for 
this project’s implementation process.  The methodology used was a non-randomized quasi-
experiment with purposive sampling of allogenic patients that included a retrospective chart 
review measuring 30-day readmissions, demographics, and the number of patients discharged 
post-transplant.  The Wilcoxon Signed Ranked Test was utilized to demonstrate statistical 
significance in 30-day readmission rates through post-transplant knowledge and managed care.  





The Effects of a Survivorship Care Plan on Hospital Readmission Rates in Allogenic Stem 
Cell Transplant Patients 
 
 The purpose of this proposal is to detail a DNP Program Development and Evaluation 
project that aims to reduce common complications and readmission rates of allogenic SCT 
patients by providing transitional care management utilizing survivorship care plans (SCPs) at 
an academic facility in Arkansas.  This proposal will describe the incidence of readmissions 
within an acute care setting and outpatient oncology clinic and its significance among the 
allogenic SCT patients.  Background information of SCTs and complications leading to 30-day 
readmission to the hospital is described.  Literature supports the use of SCPs to enhance 
patient understanding of common complications post-transplantation and decrease 
complications that lead to 30-day readmissions to the hospital.  A non-randomized quasi-
experiment design, consisting of pre-and post-intervention groups, will be used to evaluate 
SCT efficacy.  Lastly, project results highlight effectiveness of a SCP on 30-day readmission 
rates, the extrapolation of results, and methods to promote project sustainability.   
Background and Significance 
Allogenic Stem Cell Transplantation  
The first successful stem cell transplant performed by Dr. E. Donnall in Cooperstown, 
New York in 1957, paved the way for over one million stem cell transplants executed worldwide 
(Australian Cancer Research Foundation, 2020).  A SCT is a medical procedure in which healthy 
stem cells are used to replace defective bone marrow of patients with hematologic malignancies 
such as multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, acute myeloid 
leukemia, neuroblastomas, germ cell tumors, amyloidosis, and autoimmune disorders including 
systemic lupus erythematosus and systemic sclerosis (University of Michigan 2020; John 




complications encompassing bacterial and fungal infections, cytomegalovirus, bleeding, graft vs 
host disease, interstitial pneumonitis, hepatic sinusoidal obstruction syndrome, graft failure, 
mucositis, nausea, vomiting, diarrhea, secondary new cancers, infertility, and sexual dysfunction 
(Bejanyan et al., 2015).      
Over the last 50 years, more than one million SCTs have been performed worldwide with 
more than 50,000 performed annually and approximately 40% of transplants being allogenic 
SCTs (Hamdeh et al., 2016).  According to the Health Resources and Service Administration 
(2020), a total of 22,863 transplants were reported and performed in United States in 2017, with 
approximately 60 % being allogenic SCTs (HRSA, 2020 & Levine Cancer Institute, 2017).  
Males account for 60% of allogenic SCT cases.  In the United States, the median ages for 
patients undergoing allogenic SCTs are 45-70 years old, with Caucasian Americans accounting 
for 67%, African Americans for 12%, and Hispanics for 11% for this patient population (Be The 
Match, 2020).   
In Arkansas, there is currently only one facility performing adult allogenic SCTs via 
packed red blood cells (PRBCs) or bone marrow (UAMS, 2020). This center has been 
performing SCTs since 1993 with the first allogenic transplant program beginning in 2015 
(BeTheMatch, 2020).  There were 43 allogenic SCTs performed among recipients ages 45-64 
years of age in 2015-2017. The one-year survival rate for this facility is 70.2% which is above 
the national rate of 57.1% (BeTheMatch, 2020).    
 Acute Myeloid Leukemia (AML).  AML patients will be the primary cancer population 
of focus for the implementation of a SCP during this DNP proposal.  AML is a type of fast-
growing blood cancer that starts in the bone marrow, and quickly moves into the blood 




body including the lymph nodes, liver, spleen, and central nervous system.  AML is one of the 
most common types of leukemia in older adults and accounts for 1% of all cancers (American 
Cancer Society, 2020).  AML is twice as likely to be diagnosed in men than women with the 
average age of diagnosis occurring between 45-70 years of age (Tuberville, et al., 2014).  
According to the American Cancer Society (2020), annually there are approximately 19,000 new 
cases each year occurring in the United States with approximately 11,000 deaths related to this 
diagnosis.  An allogenic SCT is the most common type of curative treatment option performed 
among AML patients (Mayo Clinic, 2020).   
Human Leukocyte Antigen (HLA).  Allogenic patients undergoing SCTs require blood 
testing to assess human leukocyte antigen (HLA) typing (BeTheMatch, 2020).  HLA are proteins 
found on most cells in the body that recognize which cells belong to the patient and which are 
foreign (BeTheMatch, 2020).  HLA matching represents the most essential barrier among the 
many elements that impact the outcome of SCTs (Tiercy, 2016). Closely matching the HLA of 
the donor to that of the SCT recipient allows for the best outcome and lower risk of 
complications post-transplantation.  There are three types of HLA donors which include matched 
related donor (MRD) where the HLA is identical, matched unrelated donor (MUD) donor where 
the HLA is unrelated, and haploidentical transplant donor where the HLA is half-matched 
(American Cancer Society, 2020).  MRD is the most preferred donor source due to improved 
clinical outcomes following transplantation, faster engraftment periods, and decreased cost of 
hospitalization following an allogenic SCT (Negrin, 2020).   
Conditioning Therapy. Prior to an allogenic SCT a patient must undergo conditioning 
therapy which is composed of chemotherapy, radiation, or both.  Conditioning therapy aims to 




the marrow spaces, and weaken the immune system of the SCT recipient in preparation to 
receive the donor stem cells (Memorial Sloan Kettering Cancer Center, 2020).  The intensity of 
the conditioning therapy is an important factor and dependent on the patient’s condition and the 
source of stem cells (Atilla, 2017).  There are two types of conditioning chemotherapy treatments 
that consist of myeloablative or nonmyeloablative.  Myeloablative SCT conditioning regimen 
consists of high doses of chemotherapy with or without radiation aiming to kill the cancer of the 
SCT recipient.   This type of regimen is used for patients that are below the age of 65 years of 
age and have few to no comorbidities (Franciscan Health, 2020).  Nonmyeloablative 
conditioning regimen consists of lower doses of chemotherapy with or without radiation aiming 
to weaken the immune system allowing the donor stem cells to take over and make a new 
immune system that will fight the cancer.  This type of transplant is reserved for patients with an 
advanced age of 65 years or older or abnormalities in one of their organ systems that will not 
allow the use of the myeloablative regimen (Franciscan Health, 2020).  According to Atilla 
(2017), the relapse and survival rates are similar with each of the conditioning therapies.   
Transplantation Phases.  The allogenic SCT process consists of five phases: 
conditioning, transplant day to engraftment, engraftment until the day of discharge, early 
convalescence, and late convalescence (Memorial Sloan Kettering Cancer Center, 2020).  
Conditioning is phase one in which an allogenic SCT patient is admitted to the hospital and 
begins conditioning therapy for the next seven days.  Phase two consists of transplantation day 
until engraftment which is when blood count recovery begins, usually during day 10 through 30.  
Phase three consists of engraftment through the day of discharge (American Cancer Society 
2020; Memorial Sloan Kettering Cancer Center, 2020).  Early convalescence is phase four in 




risk for infections occurring from discharge until one-year post-transplantation.  Lastly, late 
convalescence occurs one-year post transplantation and onward in which the immune system is 
fully recovered (Memorial Sloan Kettering Cancer Center, 2020).  
Hospitalization.  According to Broder et al. (2017), allogenic SCTs are expensive 
treatments and are among the top 10 procedures with the highest overall costs associated with 
hospital inpatient services in the United States.  Allogenic SCT hospital cost, increased by 
approximately 85% from $694 million to $1.3 billion over the time period from 2004 to 2007 
(Broder et al., 2017).  The median days for hospitalization for an initial allogenic SCT are 31 
days.  The average cost for a SCT is approximately $203,206 with 75% contributing to early 
costs (Ballen et al., 2015; Bars, 2018).  Allogenic SCT patients who undergo high dose 
conditioning chemotherapy regimens can have hospitalizations that span from days to months, 
depending on the type of transplantation, reactions or complications experienced during the 
hospitalization (Cleveland Clinic, 2019; University of Utah Cancer Institute, 2018).  Due to the 
medical complexities and multiple transition points associated with the SCT treatment, SCT 
patients have a higher risk for hospital readmissions which can lead to life-threatening issues and 
prolong recovery (Bejanyan et al., 2015).   
According to Roswell Park Cancer Institute (2013), survival rates have drastically 
improved due to advances in molecular mechanisms, adapted therapeutic conditioning 
treatments, and the increased number of SCTs performed in patients 65 years of age or older 
with nonmyeloablative conditioning therapies (Walter et al,2010; D’Souza et.al, 2017).  
Allogenic SCT related mortality has decreased due to improved supportive care, better strategies 
to prevent severe infections and the incorporation of nonmyeloablative conditioning protocols 




increase from 85% to 94% with MRD, and 63% to 86% with MUD (Roswell Park Cancer 
Institute, 2013).    
Common complications  
The most common complications may occur in the early post-transplant period 
particularly in the first 30 days (BeTheMatch, 2020).  Approximately 80% of SCT patients 
experience nausea and 45% experience vomiting (Denson et al., 2020).  Diarrhea is caused by 
several distinctive factors with acute GVHD, infections, and mucositis being the most common.  
Nausea, vomiting, and diarrhea may interfere with nutrition and the ability for the patient to take 
oral medications (Hamdeh et al., 2016 & Negrin, 2020). 
Long term complications after receiving an allogenic SCT include infertility problems 
and sexual dysfunction.  The overwhelming majority of allogenic SCT patients will experience 
infertility (Virginia Cancer Institute, 2020). Infertility is a late adverse effect occurring after a 
SCT and greatly affects quality of life in allogenic transplant survivors (Atilla et al.,2016).  
Sexual dysfunction may be experienced by allogenic SCT patients one year after transplantation 
with nearly half of men and women experiencing at least one physical sexual dysfunction during 
that time (Noerskov, et al., 2016).  Sexual dysfunction is frequently one of the most common 
long-term issues following allogenic SCT.  Treatments with allogenic SCTs are associated with 
short-and long-term toxicities affecting sexual function due to the high-dose conditioning 
regimen and gonadal function changes (Atilla et al., 2016).  Long-term complications include 
decreased libido, vaginal dryness, atrophy, and erectile dysfunction (Andreini, et al., 2017).    
Infections.  Hospital readmissions due to infections among allogenic SCT patients 
usually occur within the first 30 days post-transplant (Kaur, et al., 2019; Shain et. al., 2016).  




until engraftment has occurred (American Cancer Society, 2020).   Infections can be classified as 
bacterial, viral, and fungal, with bacterial and viral infections being the most common (Kaur, et 
al., 2019 & Sahin et al., 2016).   
Bacterial Infections.  Bacterial infections are among the chief complications of allogenic 
SCT patients with the most frequent causes being bloodstream infections (BSI) and 
gastrointestinal infection such as clostridium difficile infection (CDI) (Balletto & Mikulska, 
2015).  BSI affects approximately 20%-30% of allogenic SCT recipients with the incidence 
highest during the pre-engraftment neutropenia phase (Balletto & Mikulska, 2015).  CDI 
frequently occurs in the early post-transplant period with the average time ranging from 3 days to 
33 days after transplantation (Kaur, et al., 2019).  A study conducted by Balleto & Mikulska 
(2015), on allogenic SCT patients found that SCT recipients were affected nine times more often 
with CDI than non-cancerous patients.  The allogenic SCT patient population is at highest risk 
for CDI in the acute care setting affecting 12.5% to 21.3% of allogenic SCT recipients (Kaur, et 
al., 2019).  
 Cytomegalovirus infection (CMV).  CMV is one of the most critical viral infectious 
complications related to host immune recovery after an allogenic SCT (Cho et al., 2018).  CMV 
reactivation occurs in approximately 50% to 70% of patients who undergo allogeneic SCTs and 
may be associated with a 50% mortality rate (Boeckh, 2017).  This virus has a profound impact 
on the immune system causing gastrointestinal disease, pneumonia, retinitis, encephalitis, and 
end-stage organ disease (Boeckh, 2017; Lin & Liu, 2015).  Research conducted by Schelfhout et 
al. (2019), utilized a United States database to explore the impact of CMV on hospital services 




greater by 30% and accrued higher hospital costs compared to any other 30-day readmission 
complication.   
Graft versus Host Disease (GvHD).  GvHD is the most common and serious adverse 
effect of allogenic SCT patients. It occurs when the transplanted stem cells are identified by the 
patient’s body as a foreign entity and therefore are rejected (Be The Match, 2020).  Acute GvHD 
can develop within the first months after allogenic SCTs and occurs in 20% to 50% of patients 
undergoing allogenic SCTs (Kaur et al., 2019; BMTinfo, 2020).  The main systems affected by 
GvHD are cardiovascular, pulmonary, integumentary, hepatic, and the gastrointestinal tract 
(Leukemia & Bone Marrow Transplant Program, 2016).  GvHD increases the risk of bacterial 
and viral infectious complications such as CDI, CMV, and hepatic sinusoidal obstruction 
syndrome and many patients suffering from GvHD die from these infectious complications 
(Ghimire, et al., 2017).   
Graft failure (GF).  Engraftment is key to overall better health and long-term survival 
and occurs within the first 30 days after transplantation (Hutt, 2017).   Graft failure is defined as 
the lack of hemopoietic stem cells following an allogenic SCT. According to a study conducted 
by Madan et al. (2015), there was a positive correlation between disease type and graft failure.  
Allogenic SCT patients with malignant disease had a three times higher incidence of GF than 
those with non-malignant diseases.  Patients with a MUD had a 20% higher probability of GF 
than any other donor type. 
Bleeding.  Prolonged severe thrombocytopenia and tissue damage caused by high-dose 
chemotherapy conditioning regimens lead to increased bleeding tendencies among allogenic SCT 
patients (Labrador et al., 2015).  According to Negrin (2020), bleeding occurs in approximately 




transplantation.  The most common and life-threatening bleeding problems in allogenic SCT 
patients occur in the pulmonary and gastrointestinal systems (Labrador et al., 2015). 
Acute Pulmonary Complications.  Acute pulmonary complications, including 
interstitial pneumonitis, pneumonia, pulmonary edema, and diffuse alveolar hemorrhage are 
frequently fatal complications following allogenic SCTs affecting approximately 40-60% of 
recipients.  Acute pulmonary complications contribute to 50% of all deaths in allogenic SCT 
patients (Pena et al., 2014).    Interstitial pneumonitis (IP) is characterized by widespread 
alveolar injury in the absence of lower respiratory tract infection or fluid overload.  IP develops 
in up to 10% of allogenic SCT patients typically within four months after transplantation (Kaner 
& Zappetti, 2018; Porter, 2017).  IP results from a variety of lung insults, including high-dose 
chemotherapy or radiation exposure and undiagnosed viral infections (Porter, 2017). The median 
time of onset for IP is 15-65 days after allogenic SCTs (Porter, 2017).  Pneumonia often occurs 
in 15%-25% of allogenic SCT patients (Balletto & Mikulska, 2015).  Pneumonia is depicted as 
infection that causes inflammation of the air sacs in one or both lungs (MayoClinic, 2020).  
According to Balletto & Mikulska (2015) the median time of pneumonia after transplantation 
was 66.5 days with the mortality rate at 46%.  Pulmonary edema results from fluid overload, 
cardiac dysfunction secondary to chemotherapy, radiation therapy, and renal failure (Pena et al., 
2014).  Pulmonary edema is a noninfectious complication with a peak incidence of 20% in the 
second and third weeks after allogenic SCTs (Carreras & Cooke, 2018).  Diffuse Alveolar 
Hemorrhage (DAH) is a relevant cause of an acute pulmonary complication occurring in 2%-
14% of allogenic SCT patients.  DAH has a median onset of 12-15 days within the first month 
after allogenic SCTs (Pena et al., 2014; Carreras & Cooke, 2018).  DAH has similar 




conditioning chemotherapy and radiation, and undiagnosed infections.  DAH has a mortality rate 
of 48% in this patient population (Carreras & Cooke, 2018; Soubani & Pandya, 2015). 
Hepatic Sinusoidal Obstruction Syndrome (SOS).  SOS, previously termed hepatic 
veno-occlusive disease (VOD), is characterized by hepatomegaly, right upper quadrant 
abdominal pain or fullness, jaundice, and ascites (Negrin & Bonis, 2019).  Typically occurring in 
the first two weeks after an allogenic SCT, the incidence of SOS typically ranges from 8% to 
14% (Dalle & Giralt, 2016).  The onset of SOS can be complicated by multiorgan disease 
(MOD), characterized by pneumonia, kidney failure, liver damage and encephalopathy (Negrin 
& Bonis, 2019; Virginia Cancer Institute, 2020).  SOS is associated with a mortality rate greater 
than 80% after allogenic SCTs (Dalle & Giralt, 2015; Negrin & Bonis, 2019;).   
Oral Mucositis (OM).  OM is part of a larger category of adverse effects of mucosal 
barrier injury, which can include damage to the entire gastrointestinal mucosa (Chaudhry et al., 
2016).  Oral mucositis is an inflammatory process of the oral mucosa ranging from mild 
inflammation presenting as erythematous lesions to extensive ulcerations penetrating the 
submucosa (Durlacher, et al., 2015).  OM begins to develop within two to four days following 
the completion of the high-dose conditioning therapy and occurs in 80%-100% of patients 
undergoing allogenic SCTs (Chaudhry et al., 2016; Durlacher, et al., 2015).  According to Berger 
et al. (2018), the average cost of OM related to hospitalization among SCTs was between $10, 
558 -$42, 749.  Severe OM is considered one of the main determinants of cost in the early 
transplantation period as it can result in pain, nutritional problems as a result of the inability to 
eat, and increased risk of infections due to open sores in the mucosa prolonging inpatient 
hospitalization and increase in hospital costs (Chaudhry et al., 2016; Negrin, 2020; The Oral 




Secondary Cancer Occurrence.  The success of allogenic SCTs had led to the 
unfortunate complication of secondary malignancies after receiving high dose conditioning 
therapy (Negrin, 2020).  Risk factors for developing secondary tumors are genetic defects, high 
dose-irradiation in the conditioning regimen, HLA mismatching of the donor/recipient, and 
chronic GvHD.  B-cell proliferative disorders (BCLD) is a secondary malignancy that has a 1% 
incidence that can occur in the first year after an allogenic SCT (Camp et al., 2014).  According 
to Majhail et al. (2015), the occurrence of solid tumor cancers such as lung cancer are twice as 
high in allogenic SCT patients.   
30-day Readmission Rates.   
The Centers for Medicare and Medicaid Services (CMS) uses 30-day unplanned 
readmission rates under the Hospital Readmission Reduction Program as a standard to penalize 
hospitals with high rates of readmissions for certain medical conditions (Dhakal, et al., 2019).  In 
2015, the Oncology Care Model was initiated by the CMS to help with the increasing health care 
demands and cost of care for cancer patients.  This model aims to provide quality care at the 
same or lesser cost to susceptible patients such as allogenic SCT recipients with unplanned 
readmissions due to common post-transplant complications.    
Allogenic SCTs are associated with elevated costs related to 30-day readmissions for 
post-transplantation complications resulting in prolonged hospitalizations and poor survival rates 
(Broglie et al., 2019; Dhakal et al., 2019).  According to Kaur et al. (2019), more than 50% of 
readmissions among allogenic SCT patients occur within the first 30 days post-transplantation.  
Patients with blood cancers, such as AML, generally have a higher rate of 30-day readmissions 
related to transplantation complications such as infections at 43%, gastrointestinal symptoms at 




Shahid et al. (2019), the median time for readmissions post allogenic SCT discharge was 22.5 
days with the median length of stay at 12 days.  A cohort study of patient data from the United 
States Nationwide Readmission Database detailed the overall incidence of 30-day readmissions 
was 24.4% among allogenic SCTs in United States hospitals (Seto et al., 2018; Levin, 2019 ).  
Rauenzahn et al. (2015), conducted a cohort study on 91 patients undergoing an allogenic SCT 
and found that 35 patients, 38%, were readmitted within 30 days of discharge, and were usually 
affected by infection, fever, and GI issues.   
30-day Readmission Risk Factors.  According to Bejanyan (2012), risk factors that 
affect 30-day readmissions, include myeloablative conditioning regimens with high-dose 
radiation and infections occurring during the allogenic SCT.  Springer et al. (2015), asserts that 
30-day readmissions are most prevalent among older adults with a median age of 59 years, high 
rates of infection during inpatient hospitalization, and prolonged initial hospital stay past 30 days 
after an allogenic SCT.  Rauenzahn et al. (2015), found that male gender and a diagnosis of 
AML versus other cancers were all predictive risk factors for 30-day readmissions.   
Survivorship Care Plans (SCPs) 
  The American Society of Clinical Oncology recommends that every survivor should 
receive a SCP after allogenic SCTs (Rauenzahn et al., 2017).  SCPs are documents that 
summarize a patient’s cancer treatment and provide early follow-up directions and treatment 
outlines to prevent and manage post-transplant health-related complications (Chaput, 2018; 
Memorial Sloan Kettering Cancer Center, 2020).  The urgency to incorporate survivorship 
follow-up care by 2025 is important as the requirement for oncology services is expected to 




tools to aid in transition of care and facilitate communication between specialty providers and 
primary care providers (Majhail et al., 2019; Oancea & Cheruvu, 2016).   
Barriers to SCP Dissemination. Traditionally, primary care providers have been 
uncomfortable managing the care of the increasing number of cancer survivors due to the lack of 
awareness for how to identify and treat complications (Jacobsen et a., 2018).  Rooij et al. (2017) 
specified healthcare providers noticed poor prognosis was the key barrier with communicating 
health concerns among allogenic SCT patients (Rooij et al., 2017).  According to Birken et al. 
(2018), concluded further barriers involved a lack of coordination among healthcare providers 
resulting in omission of recommended services or a lengthy SCP with duplication of information 
(Birken et al., 2018).  Mayer et al. (2015), determined the shortage of oncology providers 
resulted in providers not completing and delivering the SCPs post-treatment.   In addition, this 
study found the lack of a standardized format led to excessive time spent preparing SCPs.  
Selove et al. (2016), deduced that poor support for survivors physical and emotional needs 
attributed to major factors for SCP dissemination in post-treatment care.   
 Finally, socioeconomic status and age are other factors noted as contributable obstacles 
to unsuccessful implementation of SCPs.  Older adults tend to have a decreased ability to recall 
information and people with lower socioeconomic status may have decreased health knowledge 
and information delivery (Rooij, 2017).  Klemanski et al. (2016), concluded that a shortage of 
funding, inadequate access to care, and decreased information on utilizing reimbursement 
opportunities for SCPs were all barriers to implementation.   
Inconsistencies to SCP Dissemination 
In clinical practice the implementation and dissemination of SCPs have been low to 




al., 2017; Klemanski, Browning, & Kue, 2016).  According to Klemanski et al. (2016), 
additional inconsistencies include the absence of reimbursement, formatting consensus, cost of 
documentation, and sustainability.  Many transplant facilities commonly underuse SCPs because 
of inadequate resources or the shortage of evidence regarding the effectiveness on patient 
outcomes (Majhail et al., 2019).  According to Klemanski et al. (2016), the duties for composing 
the survivor care plan were very time consuming for one person.  Jacobsen et al. (2016), reported 
other inconsistencies included patients being unsure of the benefits from receiving a SCP, the 
design of a SCP for diverse populations, and people with low health knowledge.   
Financial Implications of SCT 
  Allogenic SCT patients sometime experience financial problems associated with long-
term recovery and complications after SCTs (Denzen et al., 2016).  According to Broder et al. 
(2017), the median cost for conditioning chemotherapy and 30-day readmission was $289, 283.  
A retrospective survey among allogenic SCT patients found that 73% reported their sickness and 
transplantation had a financial impact on their household with 47% reporting household income 
was decreased by 50% (Khera et al., 2015).  Many patients must relocate temporarily to be near a 
SCT facility and must stay several weeks to months after transplantation (Abel et al., 2016).  
This causes problems with transportation to appointments, travel expenses, and extended time 
away from work.  Financial difficulties can contribute to poor treatment adherence, higher levels 
of stress, and poor overall health particularly among post allogenic SCT patients (Abet et al., 
2016).   
In conclusion, common infectious complications after an allogenic SCT necessitate 
readmissions within the first 30 days post transplantation (Cho et al., 2018).  Allogenic cancer 




contribute to psychosocial and financial strains (Oancea & Cheruvu, 2016).  Utilizing SCPs may 
improve surveillance and coordination of care among healthcare providers and identify common 
complications post transplantation, resulting in a reduction in 30-day readmissions.  
Problem Statement 
The problem statement for this DNP program development and evaluation project is that 
allogenic SCT patients often experience hospital readmission rates within 30-days of discharge 
due to complications post-transplantation.  Providing allogenic SCT recipients with information 
on preventative measures and the signs and symptoms of complications prior to hospital 
discharge may improve patient reporting of adverse events.  It is expected that these enhanced 
understanding combined with close follow-up appointments and the frequent use of a SCP 
questionnaire will increase patient familiarity of post-transplant care leading to reduced 30-day 
readmission rates for allogenic SCT patients. 
Purpose Statement 
 The purpose of this DNP program development and evaluation project is to decrease 
hospital readmission rates that occur during the first 30 days after transplantation in allogenic 
SCT patients at an academic hospital.  Patients will gain evidence-based education on 
preventative measures and common complications through the initiation of SCPs.  The SCP 
Questionnaire will be utilized during the discharge process and weekly in the outpatient clinic 
follow-up visit to help improve the gap in care for common complications after transplantation. 
PICOT Question 
 (P) In allogenic SCT patients, (I) how does the addition of a SCP, (C) compared to 
current discharge practice, (O) effect 30-day readmission rates (T) within 10 weeks?  




Project Objectives  
The objective of this needs assessment was to ascertain the gap in care, resulting in 30-
day readmission rates among allogenic SCT patients.  A gap in care was identified by several 
key stakeholders of an oncology team at an inpatient facility in Arkansas.  These key 
stakeholders wanted to identify barriers and conjure solutions to help improve patient health 
outcomes.   
Participants 
The targeted contributors of this needs assessment were chosen as key stakeholders on 
implementing a practice change among allogenic SCT patients.  The head of the stem cell 
transplant department is an essential component and overseer for this project. The clinical service 
manager of the oncology unit, an Advanced Practice Registered Nurse (APRN) will help with 
implementing change in the unit.  The Director of Nursing will serve as resource and is a key 
stakeholder for this project.  Additional participants include the inpatient oncology staff and 
oncologists.  All stakeholders have provided insight on the gaps of care for allogenic SCT 
patients and serve as site champions encouraging the implementation of to reduce common 
complications and 30-day readmission rates post-transplantation.  
Rationale of the Needs Assessment 
Many patients at this academic facility are discharged with little education regarding 
post-transplantation care after an allogenic SCT.  Identifying gaps in care is crucial to address in 
this population as it could decrease 30-day hospital readmissions and establish preventative 
measures to improve patient knowledge of common post-transplant complications.  The result of 




at this academic hospital, identifying gaps in current processes that result in readmission to the 
hospital within 30 days. 
Data Collection Tool 
 The Bone Marrow Needs Assessment questionnaire was given to the eight key 
stakeholders to understand the needs that should be met when implementing this practice change 
to oncology patients.  The main objectives were to assess staff readiness and gather concepts and 
ideas for a practice change.  Eight open-ended questions were created and presented to the key 
stakeholders with an open comment section left for any additional commentary.   See Appendix 
K for Needs Assessment survey. 
Sample, Sample Size, and Sample Procedure 
 Convenience sampling was used to select the participants for this Needs assessment.  
Participants were chosen based upon their degree of involvement in the care of oncology 
patients.  A total of eight interviews occurred, with eight-open-ended questions given to the 
nursing staff and key stakeholders.   
Implementation and Data Analysis 
 Each interview was conducted in a quiet setting in the unit’s conference room at the 
hospital, for approximately 15-20 minutes on the afternoon of June 24, 2020.  Clarification was 
provided for all questions and promotion of ideas were offered to interviewers.  Key findings 
from the questionnaire included poor discharge processes, a lack of resources, workload demand, 
poor patient education, and recurrent readmissions among allogenic SCT patients.  All the key 
stakeholders agreed that readmissions were a major concern and that education is not properly 
provided to the patients and families.  Many staff members expressed key barriers such as failure 




ineffective discharge planning.  All of the participants were willing and ready to participate in 
the project.  Support and advice were received from the key stakeholders during their interviews.  
Many staff members recommended to employ a designated discharge nurse to ensure that every 
patient was discharged appropriately and received patient education.   
 Through the use of the gathered information, contributing factors identified as gaps of 
care were patient education, discharge processes, and readmissions at this inpatient facility.  The 
data collected will be used to address all concerns to establish a practice change for at this 
inpatient facility.  After evaluation of the Needs Assessment results, the project team will meet to 
discuss health outcomes and possible barriers to change implementation.   
Aim and Objectives 
The aim of this DNP project was to utilize survivorship care plans for allogenic SCT 
patients prior to hospital discharge in order to reduce 30-day readmission rates.  There was not a 
discharge education protocol in place to review common complications and preventative 
measures for allogenic SCT patients.  Following protocol implementation, this project expected 
to reduce readmissions rates among allogenic patients by 50% by March 2021.  The objectives 
were as followed: 
• Improve patient understanding regarding common post-transplant complications and 
preventative measures by 75% through the use of the SCP Questionnaire  
• Distribute survivorship care plans to 50% of allogenic SCT patients prior to discharge 
from the hospital 
• During the initial outpatient follow-up visits, 100% of post allogenic SCT patient’s 
education will be evaluated utilizing the SCPs with a questionnaire followed by repeating 




• During the outpatient follow-up visits, 75% of allogenic SCT patients will complete the 
full 4 weeks of post-discharge SCP Questionnaires.   
• Decrease 30-day readmission rates of allogenic SCT patients by 50% 
Review of Literature 
 In order to gather background information about allogenic SCT patients and SCPs a 
review of literature was conducted to find evidence-based information and research articles using 
the key words allogenic, stem cell transplants, bone marrow transplant, survivor care plans, 
common complications, infections, and graft versus host disease.  A detailed search strategy was 
conducted with Dr. Tony Stankus utilizing the following databases: CINAHL, PubMed, Google 
Scholar, Web of Science, Bone Marrow Donor Program, and the American Cancer Society.  The 
search was limited to peer-reviewed articles and journals written between 2015-2020.  Inclusion 
criteria were studies that demonstrated impact of 30-day readmission rates, infection, bleeding, 
graft vs host disease, interstitial pneumonitis, hepatic veno-occulsive disease, graft failure, 
mucositis, nausea, vomiting, organ damage, relapse, secondary new cancers, abnormal growth of 
lymphatic tissue, infertility, hormone changes in the thyroid and pituitary glands, cataracts, and 
sexual dysfunction (American Cancer Society, 2020).  Exclusion criteria included research more 
than five years old, children less than eighteen and research that was not written in English.  
Twenty articles were accepted after inclusion and exclusion criteria was applied.  See Appendix 
C for EMSON Evidence Table. 
 
Survivorship Care Plans 
Discharged patients after an allogenic SCT can experience a difficult transition as they 




tools that improve communication between healthcare providers and patients and can ease 
transitions from the acute care setting to the outpatient setting (Donohue et al., 2017).  A SCP 
has the ability to decrease distress by increasing the patient’s understanding of common 
complications and evidence-based preventative measures (Denzen et al., 2019).  In 2020, The 
American College of Surgeons’ Commission on Cancer (ACos Coc) revised their 2016 
accreditation standards requiring all cancer programs to deliver a SCP to 50% of survivors to 
now only strongly recommending a SCP post-transplantation (Christensen, Agee, & Bellomo, 
2020).  The ACoc Coc’s amendment to the scope of standards in 2016 was due to only 21% of 
cancer institutions meeting the accreditation standards. 
SCP Components 
A SCP is a detailed documentation given to a cancer survivor prior to discharge that is 
tailored to included specific information pertinent to the patient’s type of cancer and 
individualized treatment plan (National Cancer Institute, 2020).  A SCP includes information 
about the cancer diagnosis, conditioning regimen treatment with specific drug names, number of 
dosages, number of cycles, along with radiation type, number of dosages, and surgical 
procedures performed.  The SCP follow-up plan should contain specific recommendations for 
ongoing care that include a detailed schedule for oncology appointments, surveillance testing, 
and identifying and managing long-term and late effects.  Health promotional strategies may also 
be included to provide information on comprehensive care for each body system, central catheter 
care, smoking cessation, alcohol and dietary modifications, and regular weight-bearing exercises.  
The oncology providers and the treatment facility’s contact information should be included in the 
documentation.   Lastly, Rooji et al. (2017), suggested including information to help meet the 





The primary goals of a SCP are to improve health outcomes and enhance patient 
knowledge of preventative measures and common post-transplant complications (American 
Cancer Society, 2020). Seventy percent of cancer survivors reported expansion of knowledge 
with the ability to manage their condition and side effects when an oncology healthcare provider 
verbally explained their follow-up care and provided a copy of their SCP after their treatment 
(Kenzik et al., 2016; Morken et al., 2019).  According to Morken et al. (2019), 93% of survivors 
reported receiving a paper copy was more effective than electronic copies at the end of their 
transplantation and served as a reminder of follow-up appointments and provided education on 
future complications (Morken, et al., 2019).  Majhail et al. (2019), described 60% of survivors 
reported satisfaction with their SCP and stated improved knowledge and understanding about 
their cancer, treatment regimens, and follow-up care.  According to Phillips et al. (2020), and 
Brant et al. (2016), 70% of survivors were able to make better health care decisions which 
improved their follow-up compliance and care coordination with their healthcare providers. 
Provider Perception 
Seventy percent of healthcare providers in a Canadian Wellness Cancer program 
indicated that SCPs were helpful with increasing their own understanding of treatments given 
and transplantation side effects (Caput, 2018).  Kanagasundram & Amini, (2019), found that 
86% of healthcare providers reported that SCPs integrated continuation of health, physical, and 
physiological routines (Kanagasundram & Amini, 2019).  According to Garcia et al. (2016), 70% 
of clinicians were highly satisfied with the use of SCPs and shared positive attitudes towards 
their usage and effectiveness on improved patient care (Brant et al., 2016; Garcia et al., 2016).  A 




reported they were more susceptible to discuss survivor care issues with patients that had 
received SCPs when compared to those who did not.  According to Stricker (2019), the use of 
SCPs demonstrated improved provider knowledge of cancer disease, better surveillance among 
healthcare providers, and better quality and coordination of care.    
Implementation of SCP   
As survivorship rates continue to increase and institutions aim to overcome impediments 
to SCP compliance, it is valuable to work as a multidisciplinary team and employ the necessary 
tools to ensure the distribution of SCPs (NextPath, 2020).  Implementation of SCPs involves 
organizational resources, adequate electronic systems, standardized templates, and in-service 
training for SCP usage (Rooij, et al., 2017).  In a systematic review performed by Birken et al. 
(2018), several cancer programs successfully implemented a SCP plan of action by proactively 
developing dedicated champions.  This study also suggested the designated champions should be 
responsible for generating, completing, and providing the SCP to patients at the end of 
transplantation.  Mayers et al. (2015) found that efficient implementation of SCPs can be 
generated by a semi-automated system that recognizes the date the patient’s treatment ends, 
efficient times to deliver the SCP at discharge, and create functions that could track usage.  The 
Centers for Disease Control and Prevention (CDC) has a Comprehensive Control Center 
designed to support oncology providers with navigating through barriers with SCP 
implementation.  Oncologists are able to utilize the Comprehensive Control Center to receive 
help with creating and evaluating SCPs in efforts to improve patient knowledge and outcomes on 
common complications post-transplantation (CDC, 2019).   




According to Morkel et al. (2019), implementing SCPs into the electronic health record 
(EHR), reduces time and resources needed to compile a SCP.  SCPs can offer information on 
financial resources which could reduce the likelihood of patients abandoning follow-up 
appointments and financial distress among cancer patients (Thom et al., 2019).  Coughlin & 
Dean (2019), concluded financial material placed in the SCP could help provide guidance on 
how to access institution-specific resources, public funds, and other charitable assistance 
programs (Coughlin & Dean, 2019).     
Prevention Strategies to Reduce 30-day Readmissions 
Antibiotic and Antifungal Therapy 
Infectious complications remain a clinical challenge for allogenic SCT patients especially 
during the early phase after transplantation (Ullmann, 2016).  The use of prophylactic antibiotics 
during the pre-engraftment phase has been the gold standard of care during hospitalization over 
the past 20 years (Horton et al, 2019).  According to Aoun (2015), empiric therapy is vital as the 
early detection of invasive infections is challenging and mortality is increased by 30% when 
therapy is delayed.  Antibiotic and antifungal prophylaxis therapy has demonstrated its ability to 
reduce the incidence of severe complications resulting in readmissions by 5.6%.  Lastly, Busca 
& Pagano (2016), found prophylactic use of antifungal therapy medications reduced the risk of 




Follow-up appointments after the discharge process are an essential part of improving 




evaluation of diagnosis, adjusting and reconciling medications, and catching new incidental 
complications after an allogenic SCT (Rockney & Dressler, 2019).  In a systematic study 
conducted by O’Marcondes et al. (2019), 30-day readmissions were reduced by 2% with prompt 
follow-up appointments within a week of discharge.  According to Jackson et al. (2015), follow-
up appointments within 14 days after discharge was associated with a 19.1% reduction in 30-day 
readmissions among high-risk allogenic SCT recipients.  A study conducted by Mars (2018), 
demonstrated that post-discharge follow-up telephone appointments within 72 hours are likewise 
effective at reducing 30-day readmissions by 10% allowing healthcare providers to monitor for 
common complications post-transplantation.  
Post-Discharge Education 
 Patients with allogenic SCTs have unique health care needs and discharge educational 
materials must prepare patients to safely manage their health care and medical complications at 
home.  Educational preparation throughout the patient’s hospitalization and especially at 
discharge has the potential to reduce 30-day readmissions by 15% (Ridgeway, 2018).  Healthcare 
checklists have produced dramatic gains in patient safety and ensures that each healthcare 
provider is presenting the same content to each patient and post-discharge information is 
provided.  According to Ali et al. (2018), post-discharge education should include information 
about medications, infections and prevention tips, healthy eating, and signs and symptoms to 
immediately report to the oncology healthcare team.   According to Ridgeway (2018) post-
discharge education should include tips on oral hygiene, skin management, venous access device 
care, outpatient clinic routine, dehydration prevention, signs and symptoms to report, and 




essential information needed to continue safe and effective methods of care at home to post-
allogenic SCT patients (Ali et al., (2018); Ridgeway, (2018).   
Survey Tools 
The European Organization for the Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC-QLQ) was developed in 1996 by The European Organization for the 
Research and Treatment of Cancer to assess quality of life in patients with various types of 
cancer (Radisic, 2020).  The EORTCQ-LQL 25 is an instrument used to assess perception and 
satisfaction of cancer patients in regard to health-related quality of life information (Pinto et al., 
2014).  This questionnaire consists of 22-item Likert-style questions with two open response 
questions.  The Likert scale can be used to measure the relative intensity of responses along a 
range.  The Likert-style questions utilize a 1 to 4 scale, with 1 rating as not at all, and with 4 
rating as very much.   These items assess the cancer recipient’s perception of characteristics 
about their disease and treatment, and the satisfaction of the information received.  The 
EORTCQ-LQL 25 survey offered cancer patient the opportunity to explain if more or less 
information should be received and the type of information that should be included in the 
questionnaire.   
According to Asadi-Lari et al. (2017) this questionnaire is a reliable and self-reported 
instrument that can be used in any cross-cultural observation or intervention study.  Asadi-Lari et 
al. (2015) explained this questionnaire showed a relevancy and clarity at 86% and an overall 
appropriateness at 94% with measuring the perception of information in cancer patients.  This 
questionnaire has been tested in large international and multicultural studies and is reliable and 
applicable in cancer patients at different phases.  The EORTCQ-LQL 25 questionnaire can be 




treatment stage (Arraras, et al., 2016).  The validity of the EORTCQ-LQL25 questionnaire can 
be useful for baseline assessment and intervention measures to accommodate information 
availability for patients upon discharge (Pinto, et al., 2015). 
The Survivorship Care Plan (SCP) Questionnaire is an independently designed 
questionnaire strictly used for the purpose of this project.  The design of this questionnaire was 
based on a study conducted by Hennell et al. (2004) on the development and validation of a 
Patient Knowledge Questionnaire (PKA) for patients with early rheumatoid arthritis.  The SCP 
Questionnaire was developed to measure allogenic SCT patient’s knowledge on the education 
provided at discharge on the components of their SCP.  The SCP Questionnaire is comprised of 
eight multichoice questions with a choice of four responses.  Specifics areas from the 
components of the SCP were identified for testing in the questionnaire which included: signs and 
symptoms, drug therapy, monitoring, and preventative measures.  Questions were written 
without jargon or difficult terminology to aid in understanding (Hennell et al.,2004).  In order to 
prevent the possibility of certain responses consistently selected in error, questions were worded 
in various ways (Hennell et al.,2004).  This questionnaire will be used to assess knowledge 
attainment before and after receiving a SCP.   
In conclusion, the proposed DNP program development and evaluation project had a 
strong foundation of evidence to support the need for the implementation of a SCP based on the 
literature review.  The review of literature highlighted the importance of compliance with the 
implementation of a SCP to provide post-transplantation information on common complications 
and preventative measures in the efforts to reduce 30-day readmission rates among allogenic 




in order to assess knowledge and information received from the SCP and further accentuated the 
need for the proposed DNP project.   
Theoretical Framework 
Lewin’s Change Theory 
This DNP program development and evaluation project was designed to assess the effects 
of a SCP on 30-day hospital readmission rates for allogenic SCT patients. The Change Theory 
created by Lewin used the stage model with the founding three elements of unfreezing, change, 
and refreezing (Petiprin, 2016).  This theory best represented the guiding framework for this 
program and development project as it provided a balance of driving forces and restraining 
forces to guide implementation and created sustainable changes in this organizations.  See 
Appendix D. 
Change Theory Concepts 
The change theory had three major concepts analyzed to address possible barriers and 
resistance to change: driving forces, restraining forces, and equilibrium (Petiprin, 2016).  Force 
field analysis, a strategic tool used to understand the necessary components for change, listed 
benefits and challenges associated with the project’s innovation (Change Management Coach, 
2015).  This theory asserted that leadership roles have a strong presence in order to sustain a 
positive change (Barrow et al., 2020).  Involving stakeholders in change was a critical aspect of 
planning for change, as it allowed for problem identification, goal setting, and action planning 
which increased staff buy-in.  The leading benefit from having stakeholders involved was the 
ability to sustain change by cultivating an atmosphere of trust, open communication, and 




Driving Forces.  Driving forces were those that pushed in a direction and caused a 
change to occur (Petiprin, 2016).  The change process was effective when commitment from the 
key stakeholders was encouraged and a supportive environment was created to promote change.   
One of the major driving forces for this project expressed by stakeholders was the need to reduce 
30-day readmissions among allogenic SCT patients.  Key stakeholders expressed their readiness 
to participate in this project and were willing to help promote an environment that was conducive 
to change and sustainability of this project.   
Restraining Forces.  Restraining forces were forces that countered driving forces and 
hindered change because they pushed change in the opposite direction (Connelly, 2017).  Staff 
members communicated their readiness to help promote an improved environment.   Many staff 
members expressed this change was a necessitated component that helped to promote better 
health outcomes for the allogenic SCT population. Many staff members expressed their 
eagerness to help promote change by displayed excitement and welcomed a new adjustment. 
There was some resistance unknown, as with any change.  Resistance occurred among staff due 
to loss of power, fear the unknown, failure, and a feeling of mistrust (Mdletye et al., 2015).  
Further restraining forces among staff included proving change was not needed or poor timing 
for change.  This PI promoted reassurance to staff members, communicated change effectively, 
implemented change in several steps, and provided support to those who were resistant to face 
those unexpected challenges,    
Equilibrium.  Equilibrium is a key concept of modern science (Scandizzo, 2019). 
Equilibrium can be raised or lowered by changes that occur between the driving and restraining 
forces (Nursing Theories, 2017). Complex adaptive systems require equilibrium in order to 




currently no interventions put in place to help reduce 30-day readmission rates of discharged 
allogenic SCT patients, so the implementation of this project improved health care outcomes.  
The results of this DNP project were used to establish and support the incorporation of this new 
practice change.  The key stakeholders’ involvement in the planning and implementation phase 
were essential to building a strong foundation to sustain the change after the project 
implementation ended.  Once the results of the program were analyzed, the key stakeholders 
were the principal constituents that devised a plan for sustainability (Wojeciechowski et al., 
2016).   
Lewin’s Change Theory Stages 
Stage One: Unfreezing.  This was the first stage in which understanding change is 
needed to help improve 30-day readmission rates (Barrow et al., 2020).  A needs assessment was 
conducted to determine barriers for readmissions.  Key stakeholders and oncology registered 
nurses (RNs) expressed the need to implement a project that addressed readmission 
complications and preventative measures.  Through the data collected from the needs assessment 
a SCP was deemed to be a resourceful tool that could be given to each patient and families to 
assist in increasing knowledge and understanding for preventative measures and complications 
post-transplantation.   
This principle investigator (PI) provided a training PowerPoint presentation during a 
scheduled meeting in October 2020 to inpatient oncology RNs and key stakeholders.  This 
PowerPoint presentation included the SCP components, SCP Questionnaire, and the aim and 
objectives for this project in the efforts to reduce readmissions.  Inpatient in-service meetings 




provided script training to each oncology RN to follow when dispersing the SCP Questionnaire 
and SCP material during discharge.   
A prearranged meeting in October 2020 was conducted in the outpatient oncology clinic 
that included the transplant coordinator, RNs, advanced practice registered nurses (APRNs), and 
oncologist.  This meeting consisted of a PowerPoint presentation that described the 
modifications occurring inpatient, the SCP components, and the SCP Questionnaire.  A copy of 
the SCP and a SCP Questionnaire was given to each of the APRNs and oncology doctors to 
familiarize themselves and review the components of each document.  
This PI reviewed the goals with the APRNs and oncologist to emphasize how the SCP 
and follow-up SCP Questionnaire would potentially aid in improving patient knowledge and 
understanding on preventative measures and complications post-transplantation. This PI 
requested that each of the APRNs and oncologists distribute the EORTC-QLQ 25 at the initial 
visit only and redistribute the SCP Questionnaire during the initial visit and weekly for two 
weeks with each discharged allogenic SCT patients.  This PI was present in the outpatient clinic 
to monitor the dispersal of both the EORTC-QLQ 25 and the SCP Questionnaire during the first 
two weeks to ensure implementation was transitioning correctly.  
This PI was available to both the inpatient and outpatient sites to help with answering 
questions and clarify the process occurring. Lastly, stakeholders and trained oncology RNs were 
able to provide input during this stage to address any resistance or developments that needed to 
occur prior to implementing the change. 
Stage Two: Change.  The method of initiating the change process occurred during stage 
two which was for implementing new practices.  Project implementation began in January 2021 




patient understanding of preventative measures and complications distributed by this PI or the 
trained oncology RN prior to the patient receiving a SCP.  Afterwards, a SCP, was reviewed with 
the patient and family by this PI or a trained oncology RN.  This PI was available to evaluate the 
inpatient oncology RN’s discharge education.  A biweekly contest in the inpatient setting was 
promoted to remind and ensure oncology RNs about implementation of this new change.   
During the initial outpatient clinic visit the EORTCQ-LQL 25 was dispersed by this PI, 
or trained APRN to assess the patient’s perception and satisfaction with information received in 
regard to their cancer treatment and care.  The redistribution of the SCP Questionnaire was given 
during the first initial visit and weekly for two weeks, by this PI, and a trained outpatient APRN, 
to assess the patient’s retention of knowledge from the components of the SCP.  This PI was 
available to aid with incorporating the EORTCQ-LQL 25 and the SCP Questionnaire during the 
initial visit with the APRNs.  This PI monitored the distribution of the EORTCQ-LQL 25 and 
follow-up SCP Questionnaires by the APRNs.  The SCP Questionnaire were collected and 
evaluated to assess if there was a differentiation of scores from discharge, the initial outpatient 
visit, and the two weekly visits.   
Through the use of the plan-do-study-act (PDSA) cycle, this process was evaluated to 
help correct deviations seen with the implementation process.  The PDSA was used to evaluate 
staff process, scheduling of appointments, patient calls received and returned, patients’ 
attendance to appointments, and weekly missed appointments by patients.  Data was collected 
and evaluated on the allogenic SCT patient’s willingness to accept the SCP at discharge and 
willingness to participate with the EORTCQ-LQL 25 and follow-up SCP Questionnaire in the 
outpatient setting. This PI tracked complications and necessary interventions that occurred 




long the patient was hospitalized related to the readmitting complication.  This information was 
dispersed weekly to both the inpatient setting and outpatient clinic to show the percentage of 
readmissions occurring during this project.   
Support and encouragement were provided to the staff by this PI regarding how the 
change was impacting patient care and outcomes. This PI continued to aid and educate those who 
were resistant by communicating the need for change and the benefits of decreasing 
readmissions for this patient population.  This PI promoted engagement from the key 
stakeholders by emphasizing their presence and support during the implementation stage to help 
encourage those who are resistant.   
Stage Three: Refreezing.  In this final stage of refreezing in Lewin’s Change Theory brought 
about establishing a new status quo (Barrow et al., 2020).  Leadership key stakeholders were 
critical for this stage to help sustain and reinforce this new change in everyday practice.  The 
efforts of this program would demonstrate the benefits of SCPs and the SCP Questionnaire on 
improving patient knowledge of post-transplant complications and preventative measures.  The 
results of the project will be disseminated to the key stakeholders, in hopes of gaining support to 
implement a permanent discharge policy with SCPs.   
Summary 
Lewin’s Change Theory was used to implement a program development and evaluation 
project to promote the distribution of SCPs prior to discharge and a follow-up SCP Questionnaire 
in the outpatient oncology clinic to allogenic SCT patients.  It was expected that patient 
knowledge would improve by providing education on common complications and preventative 








Utilizing a SCP was a logical approach to educate patients prior to discharge and was 
expected to decrease 30-day readmission rates among allogenic SCT recipients.  The project took 
place in the inpatient bone marrow unit and outpatient oncology clinic at an academic hospital in 
Arkansas.  The project included a retrospective chart review to determine diagnoses for 30-day 
readmissions among allogenic SCT patients.  Staff participation were assessed by analyzing the 
charts and ensuring that all allogenic SCT patients received a SCP. 
Project Design 
The proposed DNP project was aimed to decrease 30-day readmissions among allogenic 
SCT patients by utilizing a SCP.  The approach of this project was a quasi-experiment design 
with a pre-intervention group and a post-intervention group that were non-randomized.  The pre-
intervention group consisted of patients that were discharged prior to the implementation of the 
new SCP program.  The post-intervention group included patients that received SCPs at 
discharge and the follow-up SCP Questionnaire during outpatient visits.  The outcomes 
measured included 30-day readmissions diagnoses, demographic data, and the number of 
patients discharged after allogenic SCTs, and education retention. 
Setting 
The setting for this program and evaluation project took place at an urban academic 
hospital in Arkansas.  This facility housed 450 acute care beds, with more than 10,000 




Level One adult trauma center in Arkansas.  This was the only adult allogenic SCT program for 
the state of Arkansas.  The outpatient oncology clinic was the second setting utilized for this 
project.  The outpatient oncology clinic was also a part of the urban academic facility located in 
Arkansas and managed over 300 patients.  The clinic was composed of seven medical 
hematologists/oncologists that treated blood-related diseases, sickle cell disease, thalassemia, 
leukemias and lymphomas, as well as cancers of other organs (UAMS, 2020).   
Study Population 
The study population for this project consisted of all patients undergoing allogenic SCTs 
during the 10-week implementation period.  All participating allogenic SCT patients received a 
SCP prior to discharge.  Family members and caregivers were involved for mentally incompetent 
and non-English patients undergoing allogenic SCTs. 
Study Interventions  
The trained oncology RNs reviewed the SCP with patients in the inpatient setting prior to 
discharge.  The trained APRNs redistributed and conducted follow-up SCP Questionnaires 
during the first outpatient visit and once weekly for two weeks in the outpatient clinic.  The 
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire 
25 (EORTCQ-QLQ25) was administered during the initial outpatient oncology clinic visit to 
assess patient satisfaction and perception of their cancer treatment and care. 
Pre-Implementation Phase.  This PI introduced this upcoming DNP program and 
development project during a daily in-service meeting in October 2020, to inpatient oncology 
RN’s and key stakeholders.  A video PowerPoint was recorded to highlight the important 
components from the in-service to disperse via email to those who were unable to attend the in-




next three months with this program.  This PI met with the outpatient oncology clinic coordinator 
to schedule a time and date for the month of October that was convenient for the APRNs to 
discuss the changes occurring on the inpatient bone marrow  
The SCP was constructed by this PI to provide education on evidence-based preventative 
measures and materials on common complications.  This PI met with the key stakeholders to 
review and approve the components of the SCP prior to the implementation of this DNP project.  
The creation of a SCP Questionnaire was created during this stage with the help of this PI’s 
committee chairperson.  This questionnaire was constructed with questions that assessed 
knowledge and information contained in the SCP.  A consent transcript was created by this PI to 
serve as a guideline for trained oncology RNs to use during the admission process.  The scripted 
consent transcript detailed the aim and objectives of this project in preparation of obtaining a 
signed consent from allogenic SCT patients participating in this project.  This PI also constructed 
a discharge scripted transcript as a reference for the delivery of the SCP Questionnaire and the 
SCP during the discharge process.  Lastly, this PI met the last week in October 2020 with an 
academic institution statistical graduate student to help with formulating the excel codebook.  
The codebook consisted of information to help collect data from the chart reviews, demographic 
information, and compile project results. 
Implementation Phase.  The PI monitored the SCP distribution of the trained oncology 
nurses’ practice during this stage and provided weekly updates on the implementation rates and 
detection of potential complications that were identified using the SCP.  This PI provided a chart 
to aid in visual data on the percentage of SCPs dispersed each week by those implementing 
SCPs. Through the use of the PDSA cycle, the PI monitored discrepancies and intervened when 




collected weekly for the allogenic SCT patients.  Patient knowledge was monitored to assess if 
improvements were made weekly with the redistribution of the SCP Questionnaires in the 
outpatient clinic.   
Post-Implementation Phase.  This information was used to analyze and evaluate if 30-
day readmissions rates among allogenic SCT patients were decreased with the implementation of 
this program development project.  Data showed the negative correlation between an increase in 
patient knowledge of preventative measures through SCPs and a decrease in 30-day readmissions 
rates.  The results of the project were disseminated to the facility’s key stakeholders, the 
inpatient bone marrow unit, the outpatient oncology clinic, the academic facility, and the Eleanor 
Mann School of Nursing.  
Study Measures  
Conceptual Definitions.  The conceptual definition of the term 30-day readmission 
referred to a discharge that occurs within 30 days of initial admission.  The conceptual definition 
of the term readmission referred to a discharge that occurs after a preliminary admission.  The 
conceptual definition of the term post-transplantation patient knowledge referred to a measure of 
patient understanding of preventative measures and potential complications post-discharge.  
Operational Definitions.  The operational definition of the term 30-day readmission was 
described as a discharge that occurred within 30 days of initial admission for an allogenic SCT.  
Readmissions were measured by conducting chart reviews to determine the number of patients 
readmitted for common complications.  The operational definition of the term post-
transplantation patient knowledge was information retained from the SCP during the discharge 




analyzed using the SCP Questionnaire an instrument used to evaluate patient retention of 
information from the SCP  
Outcome Measures 
The outcomes measures for this DNP program and development project were used to 
evaluate the effect of the executed program and development change (MeInky & Fineout-
Overhold, 2015).  A retrospective chart review was performed at the clinical site to gather data 
on the number of patients with complications within 30 days post-discharge and the 
differentiation of diagnoses.  Outcome measures accessed the effect of the SCP on patient health 
outcomes.  The number of patients in the bone marrow transplant unit and the number of those 
who were discharged were monitored.  The number of SCPs reviewed at discharge were 
measured.  Patients completed the SCP Questionnaire prior to receiving the SCP and that score 
was entered into the codebook.  
Data was collected on the interventions in the outpatient clinic to prevent deterioration 
after complications were identified.  Chart reviews were used to determine if the protocol 
implementation led to a decrease in 30-day readmissions through the use of the SCPs.  The chart 
review assessed demographic data, including gender, age, socioeconomic level, education level, 
insurance, marital status: number of readmissions; readmission diagnoses; complications treated; 
length of stay with readmission.  Additional measures included the number of attended visits per 
patients, the SCP Questionnaire score at initial visit and once weekly for two weeks, number of 
telephone calls from patients who had questions about recovery, number of missed appointments, 
number of patients with complications within 30 days of discharge, differentiation of 
complication diagnoses, and interventions implemented to prevent readmission.  If patients did 




Questionnaire with them.  Outcomes measures compared pre-and post-implementation 
information to conclude the project’s impact.     
Process Measures 
There was no current practice benchmark at this facility with SCPs; however, The 
American College of Surgeons’ Commission on Cancer recommended that 50% or more SCPs 
be distributed, so the process measures for this project was to achieve 50% of SCP distribution at 
the time of discharge (Bell et al., 2017).  Process compliance was monitored weekly by this PI.  
Other process measures included the percentage of patients who completed the SCP 
Questionnaire at the initial visit and then once weekly for two weeks with the goal of 75% of 
patients to complete the SCP Questionnaire at each point in time.   
Balancing Measures 
Balancing measures of this DNP project were used to assess both positive and negative 
outcomes of the implementation process.   Balancing measures for this DNP project included the 
number of readmissions, length of stay after readmission, and costs associated with readmission 
and hospitalization.  The current 30-day readmission cost for this clinical facility was unknown, 
but a cost analysis was completed for the 30-day readmissions post-implementation.  
Benefits/Risks 
Benefits of this DNP program included the application of an evidence-based practice 
intervention through the use of SCPs prior to discharge to improve patient knowledge of 
preventative measures and common complications.  There was minimal potential for emotional 
or psychological strain when this PI or oncology RN reviewed the SCP with the patient.  The risk 
of these harms was minimized by providing a private atmosphere during the discharge process 




confidentiality and patient’s privacy.  Oncology RNs were well-informed on the importance of 
providing an open pathway for communication with patients during the discharge and SCP 
instructions.  There were no suspected economic risks of harm related to the study intervention.   
Subject Recruitment 
The subjects were recruited and consented by purposive sampling on all allogenic SCT 
patients admitted for transplantation by this PI, site champion, or a trained oncology RN during 
the admission process to explain the project’s purpose, procedures, risk, benefits, and 
confidentiality.  All direct oncology RNs were trained prior to project implementation by this PI.   
Consent Procedures 
This DNP program development and evaluation project obtained consent from all 
allogenic SCT patients participating in this project.   All patients that met inclusion criteria for an 
allogenic SCT were consented by this PI, site champion, or a trained oncology RN during the 
admission process to explain the project purpose, procedures, risks, benefits, and confidentiality.  
See Appendix N for Informed Consent Form.   
Subject Costs and Compensation  
Allogenic SCT participants did not receive cost or compensation for taking part in this 
project. The two top performing oncology RNs were rewarded with gift cards for their 
participation in this project.   
Project Timeline 
 The project implementation began January 13, 2021 and ended March 27, 2021.  Data 
was collected and evaluated from late-February 2021 through March 2021.  April 2021, the 





Resources Needed and Economic Considerations 
 The discharge program was not associated with any cost to the participants of the project.  
The resources used for this project required paper, ink, staples, and two gift cards which all 




The implementation phase of this project was planned and applied by all stakeholders and 
team members; however, modifications to the interventions were necessary during the course of 
this project despite the meticulous planning efforts.  Plan, Do, Study, Act (PDSA) cycles were 
utilized to analyze the implementation process and in-service meetings were scheduled to discuss 
processes, outcomes, and balancing measures to ensure that complications were addressed during 
the implementation process.  The following discusses the implementation process, PDSA cycles, 
deviations from the project’s timeline, and the current process flow during the implementation 
process.    
Implementation Process 
 While awaiting Independent Review Board (IRB) approval, this PI created a PowerPoint 
presentation to present to the inpatient Registered Nurses (RNs) and Advanced Practice 
Registered Nurses (APRNs).  A meeting with the oncology Clinical Service Manager (CSM) and 
Advanced Practice Partner (APP) of the bone marrow unit discussed their cooperation and 
support to promote adherence with the implementation process.  IRB approval was obtained on 
Monday, January 11, 2021, with the implementation process beginning on Tuesday, January 12, 





 After IRB approval, the initial intervention occurred with nursing staff education.  Four 
30-minute in-service project training meetings were conducted during the same week of IRB 
approval.  Training sessions were on Tuesday, January 12, 2021, and Thursday, January 14, 2021 
at 2:oo pm CST.  A third session was held on Friday, January 15, 2021 at 4:00 pm CST to 
include the night and weekend staff nurses.  The final session was on Monday, January 18, 2021 
at 2:00 pm CST in the outpatient clinic with the APRNs.  All nurses and APRNs attended the 
training sessions with a sign in sheet provided to account for each nurse and APRN.    
 Each nurse and APRN received all components of the project which included scripted 
pre-and post-transplant letters, SCP Questionnaire, EORTC-QLQ 25, and the discharge SCP 
educational material.  The pre-transplant script contained a brief description of this PI contact 
information, history of the transplant program, the purpose of the project, and expectations prior 
to discharge.  See Appendix L.  The post-transplantation script contained instructions on 
completing the SCP Questionnaire prior to discharge, the components of the SCP, and a section 
that thanked the patients for participating in this DNP project.  See Appendix M.    
The SCP educational material consisted of a ten-page packet that included a welcome 
letter to the SCP participant that detailed the materials of the packet.  A personalized and 
customizable treatment summary sheet with specific information pertaining to the patient’s 
cancer diagnosis, transplant type information, chemotherapy drugs or radiation treatment used, 
along with the transplant center’s contact information was included.  Two pages of 
recommendations for preventative care for each of the body systems, as well as information 
about central catheter line care was provided.  A two-page compilation of common 
complications post-transplantation with signs and symptoms was incorporated.   A list of 




effects were included as a reference sheet.   Lastly, the final two pages consisted of activities of 
daily living tips and suggestions for discharging from the hospital.  See Appendix I for SCP 
Patient Education Material Packet. 
The other components of the project included the SCP Questionnaire which consisted of 
eight questions that inquired knowledge of post-transplant care, preventative measures, and 
scenarios of when to contact their oncologist.  See Appendix J for SCP Questionnaire.  The 
EORTC-QLQ 25 questionnaire consisted of nine questions that inquired information received on 
aspects of their disease and treatment and an open commentary section.  See Appendix K for 
EORTC-QLQ 25.   
 In-service meetings reviewed the purpose and tentative objectives along with the 
importance of gaining consent for each of the participants taking part in this project.  Time was 
allotted for questions about the project and the project’s components after each in-service 
meeting.  A detailed reminder email was sent with instructions for the project, each of the 
aforementioned project documents, along with a PowerPoint Presentation, to every inpatient 
nurse on the bone marrow transplant unit, the CSM, the APP, and the outpatient clinic APRNs to 
use as a reference.  All of the project’s consent forms, SCP Questionnaires, and discharge SCP 
education materials were located at the central nurse’s station for easy access.  This PI accepted 
new participants into the Survivorship Care Plan program after the completion of the initial in-
service meeting.  The official start date for acceptance of new stem cell transplant participants 
into this project was Wednesday, January 13, 2021. 
Accepting Stem Cell Transplant Participants 
 On January 13, 2021, the project’s first allogenic SCT patient elected to participate in the 




following day, this PI discussed the objectives, risks, and benefits of participation in the project.  
After receiving verbal feedback about all the components of the project, the consent form was 
reviewed and signed.  Three additional patients were admitted for their allogenic stem cell 
transplantation and were consented by this PI during the dates of January 13, 2021 through 
January 21, 2021.  
 Four additional patients were admitted undergoing their allogenic stem cell 
transplantation and were consented by this PI and nursing staff during the dates of  February 3, 
2021 through February 12, 2021.   
 Three final patients were admitted undergoing their allogenic stem cell transplantation 
and were consented by the oncology nurses during the dates of February 23, 2021 through March 
5, 2021.  
 An educational session was provided explaining the expectations for discharge day and 
the following three weeks after discharge.  This PI explained to each participant that an eight 
question SCP Questionnaire would be dispersed prior to discharge from the hospital and will 
assess baseline knowledge of common complications and preventative measures associated with 
allogenic stem-cell transplantation recovery.  After the completion of the SCP Questionnaire, the 
discharge SCP education material was distributed to them for post-transplantation care.  After 
reviewing all components of the project, this PI answered questions to ensure understanding 
from each participant who signed the consent form.  The time spent with each patient was 
approximately 45 minutes after reviewing all project objectives, the educational discussion, 
interventions upon discharge, and the question-answer period.  
The first two consented patients were administered the SCP questionnaires by this PI 




questions about self-care after completing the questionnaire and received their discharge SCP 
educational material. Participants were discharged on the same day following the completion of 
the questionnaire.   
Participants’ knowledge about their disease, treatment, and recovery concerns were 
assessed using the EORTC-QLQ 25 during the initial follow-up outpatient appointment. 
Knowledge attainment was reassessed during the initial visit with the redistribution of the SCP 
Questionnaire.  Reassessment of knowledge attainment continued weekly during outpatient 
clinic visits for the next two weeks through the use of the SCP Questionnaire by the APRNs.    
Monitoring of Participants  
 This PI attended weekly in-person chat meetings from February 1, 2021 through March 
22, 2021 with the oncologists, bone marrow CSM, bone marrow APP, and other health 
professionals to assess and discuss each of the allogenic patient’s current health status and 
anticipated discharge dates.  An email was sent after each meeting to the nursing staff and 
APRNs to notify them of the patients to discharge for the upcoming week.   
This PI met with each of the patients to reinforce expectations at discharge with the SCP 
Questionnaire and thereafter approximately 14 to 21 days post-transplantation.  Each of the 
meetings ended with a question or commentary section to ensure patients concerns were voiced 
and answered. 
This PI collected SCP Questionnaires and EORTC-QLQ 25 weekly from both outpatient 
and inpatient settings and entered the data into an excel spreadsheet.  Chart reviews were 
performed from February 5, 2021 through March 20, 2021 by this PI to monitor 30-day 
readmissions post-transplantation.  This PI found no 30-day readmissions among the participants 




blood products, intravenous fluids, and electrolyte replacement related to the post-transplantation 
recovery phase and routine labs drawn to monitor post-transplantation care.   
Weekly emails between this PI, transplant coordinator, and the outpatient APRNs 
occurred to assess for missed appointments post-transplantation.  Missed appointments during 
the implementation phase were due to closure of the clinic related to inclement weather.   
Reviewing Processes and Measures 
 Data collection was updated weekly throughout the course of this project upon gaining 
consent from the participants.  Paper copies of data were stored in a secured locked cabinet with 
only this PI having access.  Electronic copies of data were secured within the project’s 
implementation site encrypted secure network.   
 Inpatient weekly meetings occurred over a 10-week span beginning January 18, 2021 
through March 24, 2021.  An initial meeting was held for inpatient RNs, CSM, and APP to meet 
and review the project’s progress on February 2, 2021.  This meeting prepared the staff for the 
discharge protocol and review the process measure to distribute a SCP to all discharging patients.  
The next meeting occurred February 3, 2021 to discuss the same measures with the outpatient 
clinic APRNs as patients would continue to receive the SCP and EORTC-QLQ 25 in the 
outpatient setting. The next meeting held approximately two weeks later in the outpatient setting 
discussed balancing measures to decrease hospital cost by initiation of interventions to reduce 
hospitals readmissions.   The last meeting occurred on March 17, 2021 reviewed the outcome 
measures of collecting the final completed questionnaires, collecting missing data on returned 





 The initial project timeline varied when compared to the actual planned goals.  The IRB 
process began mid-October 2020 with several revisions made to the SCP proposal.  The IRB 
committee approved the protocol on January 11, 2021 and the SCT project implementation 
period began from January 13, 2021 until March 26, 2021.  See Appendix S for Final Gantt 
Chart.  The consenting period of allogenic SCT ended approximately two weeks early on March 
7, 2021.  Ending the consenting period early was necessary as allogenic stem cell transplant 
patients are typically hospitalized for 30 days post transplantation.   The collection of data after 
March 27, 2021 would run the risk of not being included in the final results of the project.  The 
projected number of participants needed for this study was not met by March 7, 2021 as time 
constraints were a determining factor.  Project enrollment was a continuous effort as patients 
were admitted at various times throughout the project for their allogenic SCT. See Appendix R 
for Implementation Timeline. 
PDSA Cycles  
  Inpatient Staff and Consenting.  This PI noted after admitting the first two participants 
for this project that patients consent forms were not completed.  This PI investigated and met 
with each patient that was admitted, but not consented. Patients reported information was given 
about the project during the admission process, but no consent form was received.   Clarification 
about consent forms were answered by this PI during a weekly in-service meeting with the 
nursing staff.  Staff expressed their uncertainties of when consents forms should be signed during 
the project.  This PI reinforced that consents should be signed within 72 hours of admission.  
This PI designated a central location for all nurses to place the signed consents in a folder for this 
PI to pick up weekly and assessed the admission process for the next several weeks and noted 




Decreased Nurse Participation.  This PI found low nurse participation during the first 
four weeks of implementation, in which eight of the 22 nurses obtained consents.  At a weekly 
meeting this PI announced there would be a contest for two ten-dollar gift cards for the top two 
nurses with the most consents during February 5, 2021 through February 13, 2021.  This PI 
announced the two winners the following week at the next meeting.  After the implementation of 
the promoted incentive, this PI assessed that all admitted patients were consented and 18 of the 
22 nurses sustained obtaining consents throughout the remainder of the project.  The four nurses 
not accounted where out on maternity leave and family medical leave.  This PI continued to 
provide support and praise while monitoring the project weekly for interventions to be 
implemented.  Each week during the 30-minute in-service meetings this PI reviewed the number 
of patients discharging each week, patients that received the SCP Questionnaires and discharge 
SCP Questionnaire educational materials, and interventions needed to continue implementation.  
 Improved Discharge Education.  The first consented allogenic SCT patient was 
prepared to discharge after four weeks of implementation.  After week five of implementation 
the following patients noted complications in the discharge process such as decreased ability to 
focus, time constraints, and nurses not reviewing educational material.  Two ten-minute meetings 
occurred on February 9, 2021 at 9:00pm CST and February 10, 2021 at 8:00pm CST to discuss 
the implementation of the SCP questionnaires the night prior to discharge to ensure adequate 
time for completion and proper review of the SCP educational material.  Both in-service 
meetings occurred as planned with 17 of the 22 employed night shift nursing staff attending the 
meetings.  This PI met individually with the remaining nursing staff unable to attend the in-
service meetings. This PI monitored the new intervention of implementing the SCP 




increase in the discharge SCP Questionnaire scores improved by the increased number of correct 
answers noted after administering during the night.  This PI found that all patients received SCPs 
and education for the remainder of the project implementing the SCP Questionnaires at night.   
 Outpatient Follow-up Appointments.  This PI met with the outpatient clinic on 
February 4, 2021 to reinforce the correct implementation of the SCP Questionnaire and the 
EORTC-QLQ 25 at the initial visit and only the SCP Questionnaire weekly for two weeks as the 
first patient was scheduled to discharge the next day.  Time constraints were noted with the 
application of the SCP and EORTC-QLQ 25 questionnaire after one week of monitored visits in 
the outpatient setting.  An in-person meeting was conducted with the APRNs to determine the 
optimal time to implement the questionnaires.  This PI and APRNs found that filling out the 
questionnaires in the waiting area was more effective to decrease time constraints.  The APRNs 
agreed to having a designated area at the front desk with a copy of the questionnaires and a list of 
the participants each week to ensure patients receive and fill out their questionnaires at check-in 
while waiting.  APRNs would collect the completed questionnaires during their visit with each 
participant and placed the completed surveys in the designated area for pick up.  After the 
implementation of this intervention APRNs verbally reported that patients were not rushing to 
fill out surveys during their visits.  This PI continued to conduct weekly meetings in the 
outpatient setting to gather data on missed appointments, readmissions to the hospital, barriers to 
distributing the SCP Questionnaire and EORTC-QLQ 25, and assessment of SCP Questionnaire 
scores.   
APRN participation in the outpatient setting was noted to be low.  After interventions 
were put in place for patients to fill out the questionnaires in in the waiting area, this created a 




March, and interventions were not put in place as the project only had approximately two weeks 
prior to ending implementation.   
Interprofessional Team Dynamics 
 The SCT project team consisted of a nurse manager, executive director, advanced 
practice partner (APP), principal investigator, registered nurses (RNs), and advanced practice 
registered nurses (APRNs).  Prior to the implementation of the project, team assurance to 
implementing quality care was established.  Further qualities of the SCT team were responsible 
for the success of this project.  These additional qualities included effective communications 
among team members, corresponding leadership roles with this principal investigator, and the 
continuous commitment of all team members in the project’s goals.   
 Weekly meetings aided to achieve constant and effective communications among the 
team members to attain optimal implementation each week.  Tasks were completed due to the 
presence of leadership members each week, team comradery, and continuous communication.   
 Professional leadership was noted in each member of the SCT team.  Effective teamwork 
was noted in this project because each member possessed leadership qualities that contributed to 
the successful efforts of implementing this project.  All nursing staff were capable and confident 
in themselves, peers, and leadership members during the implementation phase.  The SCT team 
worked efficiently with this PI and the leadership members to monitor participants, identify 
problems, and evaluate if new changes were effective using the PDSA cycles. 
 Lastly, this PI encouraged engagement in post-care of SCT patients.  The nursing staff 
and leadership members shared their concerns and opinions during each of the weekly meetings, 
with decisions made being made as a team.   




 The 30-day process flow for allogenic SCT patients involved substantial changes that 
were monitored continually during the course of implementation by this PI.  The section below 
details the improved process flow of the allogenic SCT patients.  See Appendix S for Final 
Allogenic Stem Cell Transplant Flow Chart.   
 The original flowchart consisted of a room assigned to each allogenic stem cell transplant 
patient on the bone marrow unit that arrived in the hospital admission area.  The oncology 
resident and this PI were notified via phone of the patient’s arrival to the bone marrow unit and 
the admission process was completed by the admitting RN. This PI or nursing staff invited the 
patients to participate in the project explaining the goals and aims.  The patient voluntarily 
signed the consent form within 72 hours and began their allogenic stem cell transplant process 
the next hospitalized day in preparation to receive an allogenic stem transplant from their 
perspective donor.  As the implementation phase continued the process flowcharts improved 
with each intervention used to improve the project.   
 The proposed process required modifications as the implementation phase continued over 
the 10-week period.  After the completion of the stem cell transplant a recovery period occurred 
over seven to 27 days post-transplantation in patients without complications.  Once the recovery 
period was completed and blood counts where stable patients were prepared to discharge. 
 The final process chart consisted of the night prior to discharge, the nursing staff or this 
PI met with the patient to implement the SCP Questionnaire and the discharge educational 
material.  The patient was discharged to local housing to begin their outpatient clinic visits 
within one to two days post discharge.  At the initial visit the SCP Questionnaire was 
redistributed along with the EORTC-QLQ 25 by the oncology APRNs to assess knowledge 





The evaluation of the Allogenic Stem Cell Transplant project was constant in monitoring 
process, outcome, and balancing measures.  January 13, 2021 through March 20, 2021, 11 
patients were admitted to the bone marrow unit undergoing their allogenic stem cell 
transplantation.  A 100% of the participants (N=11) were enrolled over the course of the project.  
The project enrolled five participants in January 2021 (45.4%), five participants in February 
2021 (45.4%), and one in March 2021 (.09%).  The mean age of the participants was 45 years of 
age (N=11, SD=12.82) and had a small negative skew distribution with a mesokurtic curve with 
a range of 27 to 67 years.  The mean average score of the discharge SCP (pre-test)was 85.1%, 
the mean average score of the outpatient SCP (post-test) was 100%.  See Table 1 below for 
descriptive data. 
Variables included knowledge of post-transplant care, demographics, outpatient clinic 
visit attendance, and health provider compliance.  Inpatient setting healthcare compliance during 
the implementation phase accounted for 100% (n=36) and the outpatient clinic compliance 
accounted for 100% (n=4) .  The total number of outpatient clinic visits for the 11 patients 
during the 10-week project period accounted for 97% (n=297).  Additionally, 54.5% (n=6) of 
participants had a high school education or less, 27.7% (n=3) of participants had a two-year 
degree, and .18% (n=2) of participants had a four-year degree or higher.  Of the 11 consented 
participants only one patient was African American with Caucasian ethnicity accounting for the 
remaining 10 participants.  Women participants accounted for 54.5% (n=6) and men participants 
accounted for 45.4% (n=5) of the project.  Lastly, 45.4% (n=5) of participants had an annual 
income of less than $40,000, 45.4% (n=5) of participants had an annual income more than 




$80,000. The income class was determined on a low-, middle-, and high-class system (Snider, 
2020).   




A paired sample t-test was conducted to determine if the average stem cell transplant 
participant post-SCP questionnaire scores increased significantly from the pre-SCP questionnaire 












questionnaire scores, M=100, t(10) = 3.329, p=.007, compared to before (M=85.18).  The 
Shapiro Wilk’s Test of normality indicated that the normality assumption was violated 
(W=0.763, p 0.003) the data was not normally distributed, and the sample size was also small 
(N=11).  A nonparametric test the Wilcoxon Signed Ranks Test was performed, due to the 
violation of the Shapiro Wilk’s Test.  The Wilcoxon Signed Ranks Test indicated that the post-
SCP questionnaire scores were statistically significantly higher than pre-SCP Questionnaire 
scores Z=,-2.333 p<.020.   The post-SCP Questionnaire knowledge mean demonstrated a 
significant improvement over the pre-SCP questionnaire after receiving the SCP educational 
material at discharge.     
The findings from this project demonstrated a negative correlation between the 
distribution of SCPs prior to discharge, the follow-up SCP Questionnaire during the outpatient 
visits, and the absence of 30-day readmissions among the allogenic SCT patients.  These findings 
were consistent with this PI’s and the key stakeholder’s Needs Assessment and proposed project 
objectives of reducing 30-day readmissions.  Implementing a SCP at discharge improved patient 
knowledge and understanding of preventative measures and common complications post-
transplantation and proved to have a significant impact at this academic facility.   
Missing Data 
 The collection of data for this stem cell project was difficult with a few reasons.   
Readmission data for this stem cell project was not collected because readmissions did not occur 
during the project’s time frame.  Only eight patients of the 11 discharged patients had a 30-day 
period to be evaluated.   
 There was also missing data on the phone calls received in the outpatient clinic, as only 




phone calls returned by the APRNs.  One of the patients required clarification about a post-
transplantation medication and the other patient inquired about COVID-19 vaccination post-
transplantation.  This data was not identified until the end of implementation and interventions 
were not put in place due to time constraints.  Lastly, data was not collected for one week due to 
the inclement weather and the closure of the clinic.   
Process Measures 
 Process measure one within this project included the percentage of patients who received 
survivorship care plans.  Process measures two included the correct use and implementation of 
SCPs by providers and the factors that prevented the correct use.  Process measure three included 
the correct use of the redistribution of the SCP Questionnaire and the EORTC-QLQ 25 in the 
outpatient setting.  Process measure four included measuring the percentage of patients who 
completed the SCP Questionnaire and the EORTC-QLQ 25 at the initial visit and the SCP 
Questionnaire once weekly for two weeks.  Each weekly team meeting discussed measures to 
address all insufficiencies and reported using descriptive statistics. 
Survivorship Care Plan Capture Rate 
  The SCT patients capture rate was monitored weekly through the use of the EORTC-
QLQ 25 in the outpatient setting.  There were two specific questions used from the EORTC-
QLQ 25 to help capture SCP distribution rates that directly asked the patient if written discharge 
education material was received at discharge and if tips to managing your illness at home were 
explained.   Patients were not receiving post-transplantation educational material prior to this 
project.  The goal of this project was to initiate SCPs to 75% of discharged patients, but the goal 




 Two patients discharged in January 2021, five patients in February 2021, and three in 
March 2021, all with a capture rate of a 100%.  See Table 1 for Survivorship Care Plan Capture 
Rates. 
Table 1. Survivorship Care Plan Capture Rates. 
 
Inpatient Healthcare Provider Capture Rates 
The healthcare provider capture rate was assessed by a combination of information.  The 
information received from the retrospective chart review and the two specific questions used 
from the EORTC-QLQ 25 helped to capture healthcare provider rates that directly asked the 
patient if written discharge education material was received and tips to managing their illness at 
home were explained. The information from the chart review revealed which nurse discharged 
the patient for that day and that information was corresponded with the data from that particular 
patient’s response on the EORTC-QLQ 25 questionnaire.  The collection of data revealed that 
each nurse discharged patients correctly and implemented the SCP at discharge which showed a 
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Table 2. Survivorship Care Plan Capture Rates. 
 
Outcome Measures 
 The outcomes of the SCT project demonstrated the overall success of increasing patient 
knowledge and understanding of post-transplantation care.  The outcomes evaluated include the 
SCP Questionnaire pre- and post-survey scores.   
Participant SCT Education.  SCT participants were provided a pre-and post-
educational questionnaire to determine if post-transplant knowledge improved.  The EORTC-
QLQ 25 was used to assess if patients received a SCP, tips on managing their illness at home, 
and possible side-effects of treatment.   A 100% of participants reported receiving all written 
information at discharge.  The goal of this measure was to show a post-questionnaire mean 
correlation score of 75%.  The mean of the pre-educational questionnaire was 85.1 (N=11, SE= 
4.425).  The post-educational questionnaire demonstrated an increase of 14.9% in comparison 
with a mean of 100% (n=11, SD=.00).  
The projected goal of achieving a mean score of at least 75% for post-knowledge 
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improved their overall knowledge of post-transplant care.  These results can be correlated with 
the routine use of a SCP provided at discharge as this tangible material provided a resource to 
patients after discharging from the hospital.  The information on tips for activities of daily living 
and preventative measures aided in reinforce post-transplant self-care interventions provided by 
this PI. See Table 3 for Summary of SCT Education. 
Table 3. Summary of SCT Education 
Variables M Range SD 
Age 45.6 40 12.83 
Pre-Knowledge 85.18 38 14.68 
Post-Knowledge 100 0 .000 
 
 Stem Cell Readmission Rates.  An outcome measure was to reduce the readmission rate 
by 50% by March 2021.  Of the 11 participants, no patients were readmitted within the 30-day 
period following their allogenic stem cell transplantation.  A retrospective chart review from was 
completed to demonstrate and signify a difference in samples.  The chart review revealed there 
were 22 allogenic transplants performed during October 2020 through December 2020.  Of the 
22 transplants performed eight patients were readmitted with complications of infections, GvHD, 
and pneumonia with an admission rate of 36% (n=14). 
 A nonparametric test was conducted to emphasize the difference of samples where 
readmissions was a dependent variable.  The binomial test calculated whether the proportion 
varied significantly from 36%, the pre-stem cell project readmission rate.  The p-value calculated 




discharge program was significantly different.  The project was effective in reducing 30-day 
readmission rates by 36% to 0% (N=0).  See Table 4. Stem Cell Readmission Rates.  
Table 4. Stem Cell Readmission Rates. 
 
Unintended Consequences of Project 
 The implementation phase disclosed a few incidences that were unforeseen during the 
pre-planning phase.  The events were recognized but were unable to be revised to ensure the 
corrections could be made to prior to completing the project. 
 In the outpatient clinic the APRN involvement was minimal and an unforeseen 
constraint.  APRNs did not have an active role in the outpatient setting and demonstrated a 
decreased participation in leadership roles for this project.  Interventions were not in place to 
combat this consequence which would have proved beneficial if assessed earlier in the 
implementation phase.  
Data Maintenance and Security 
Data was collected using an academic hospital system’s electronic medical record (EMR) 
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private computer with no one else to access it. See Appendix H for the project codebook.  Data 
collected includes: 
• Demographic information that included: gender, age, marital status, ethnicity, 
educational background, and socioeconomic level 
• Distribution of SCP Questionnaire from the trained oncology RN 
• Distribution of SCP Questionnaire by trained APRN or oncology doctor 
• Attendance to follow-up visits 
• Missed appointments 
• Readmissions within 30 days after allogenic SCT  
• Complications that are related to 30-day readmissions 
• Interventions in the outpatient clinic to prevent deterioration after complications 
are identified.  
Discussion 
Project Impact 
 The discharge project demonstrated substantial impacts for the participants in this project. 
The participants learned imperative preventative measures and common complications to help 
improve health outcomes post-transplantation.  Understanding preventative care measures, tips 
on activities of daily living precautions, signs and symptoms of common complications and the 
usage of common medications post-transplantation were the primary focus of the education 
provided.  The improvement of post-transplant knowledge improved 14.3% over the course of 
the project.  The evidence-based education contained in the SCPs were useful to the overall 





 The stem cell discharge program replicated many outcomes from the literature in 
reducing 30-day readmissions.  Phillips et al. (2020) found that 68.8% of post-transplant patients 
improved their post-care knowledge of cancer treatment and common complications after 
receiving a survivorship care plan.  Majhail et al. (2019) reported that 87% of survivors reported 
SCPs to be useful with understanding side effects, related treatments, and post-care health 
management.  The implementation of this program and development project at this academic 
facility reduced 30-day readmission to 0% during the 10-week implementation period.  Krames 
(2017), reported patients who received SCPs along with post follow-up care were 15% less likely 
to be readmitted or visit the emergency department.   
Economic and Cost Benefits.  
Allogenic SCT hospital costs have grown 85% over the past two decades costing nearly 
$1.3 billion annually to the healthcare system (Khrouf, 2017).  Broder et al. (2017), found the 
median total healthcare cost of allogenic SCTs were approximately $289, 283 for a hospital stay 
of 35 days.  Rauenzahn et al. (2015), concluded the median time for post-transplantation 
readmission was 14 days and a median length of stay exhibited nine days.  On average, 30-day 
readmissions cost around $40,687 depending on the complications experienced by the allogenic 
SCT patient and the severity of necessary treatment. (Cho et al., 2018).   
Through the implementation of this DNP program and development project, a reduction 
in healthcare costs and 30-day readmissions roughly saved this academic facility $18,000 per 
allogenic SCT patient on 30-day readmission rates by improving after-hospital care instructions 







 In spite of meticulous planning, there were notable limitations during this study:  sample 
size, sample profile, single facility, questionnaire usage and a short timeline are all restrictions 
and elements that will be discussed as they may affect the final results.   
 Sample Size.  The allotted timeline and slow admission of patients with acute myeloid 
leukemia admitted to the project’s facility limited patient participation in this project.  A larger 
sample size would improve the power of the project. 
 Sample Profile.  This project was limited to a specific population of allogenic stem cell 
transplant patients.  This project also excluded all patients below the age of 18, participants with 
a life expectancy of less than 30 days, those who did not have a diagnosis of acute myeloid 
leukemia, and those patients who previously received an allogenic SCT within the last year.  The 
exclusion of patients with previous experiences from multiple transplants was necessary as their 
responses could create bias and taint the results of this project.  All of these restrictions were 
necessary components needed to qualify for an allogenic transplant on the bone marrow unit and 
allowed for a homogenous sample for this project.   
 Single Facility.   The use of one facility to identify if the evidence-based interventions of 
this project improved post-care transplant patient knowledge is limiting.  Some alterations may 
be required to conduct this project into another similar facility to anticipate comparable 
outcomes.  Although there was statistical significance, each bone marrow unit has a variety of 
transplant qualifications which may not demonstrate the results of multiple facilities admitting 
allogenic patients.   
 Timeline.  The SCT project’s implementation phase was limited to approximately 10 




admit an average of 3-5  allogenic patients each month.  An extended timeline would permit a 
greater sample size that would increase the effect size of the project to improve statistical 
significance.     
Validity and Reliability of SCP Questionnaire.  The SCP Questionnaire could generate 
possible bias and limitations as this survey was strictly used for the purpose of this project and 
independently designed by this PI.  The validation and reliability of this survey could create 
further bias as it was sought content and constructed by expert reviews from this PI’s project 
committee members and a pilot test was not performed prior to implementation.    
 Limited Outpatient Clinic APRNs Involvement.  The APRNs participation was very 
limited which reduced the intended involvement with patients in the outpatient setting.  This 
limitation could create decreased opportunities for leadership involvement in the outpatient 
setting.  This limitation could lessen beneficial educational opportunities in the outpatient setting 
to improve overall patient health outcomes.   
Factors Limiting Transferability 
 The stem cell project was designed specifically for an academic facility where this PI 
performed this project.  This academic facility assembled its own standards, principles, and 
structural framework.  The care provided by each stem cell bone marrow unit are required to 
meet state and federal standards that command the level of care provided and varies among each 
program.  Because of the variations among each stem cell bone marrow program, changes may 
be required to transfer and adapt in a similar stem cell program into another healthcare facility. 
Threats to Internal Validity 
 Confounding Variables.  This stem cell bone marrow unit only performs transplants to 




patients eligible for allogenic stem cell transplants (Mayo Clinic, 2020).  Not knowing how other 
cancers may respond to this same educational material in similar facilities presents potential 
threats to the internal validity of this project. 
Efforts to Decrease Limitations 
  Limitations recognized during the implementation phase such as timeline, staff shortage, 
and sample size are difficult variables to control and affected the project’s outcome 
measurements.  The limitations such as sample profile and incentive measures were implemented 
to reduce interference with outcomes.   The sample profile exclusions were implemented as it 
eliminated the stem cell patients that received previous transplants within the last year.  This 
population would potentially alter the outcomes due to the pre-existing complications from 
previous transfusions and prior experiences and expectations from previous transplantation.  
Inclusions should be considered in projects with a larger sample size.  This PI offered two gift 
cards as incentives to help combat low nurse participation at the beginning of the project.  Due to 
staff shortage in the inpatient setting and minimum financial resources needed for 
implementation, staff members volunteered with the PI being the most consistent educator and 
data collector during this project.   
Recommendations 
 As the stem cell transplant project changes into the new discharge policy, there are 
recommendations that will increase the efficiency in providing education to patients with cancer.   
 Recommendations for future endeavors include more active interventions from the 
APRNs.  APRNs could serve as leaders and resources to collaborate with other interprofessional 
team members and improve the healthcare outcomes for this patient population.  Future studies 




outpatient clinic.  Evaluation of telephone calls placed and received by patients and APRNs 
should be monitored closely to determine information that could be gathered to further support 
efforts to increase the efficacy of future projects.    
 It is recommended that the nursing management provide an opportunity for nursing staff 
members to become leaders in this new program.  The leaders of this discharge program will 
continue to implement changes as necessary and add resources that improve the educational 
materials.  The leaders could provide online modules for continual education while using the 
same program guidelines to guarantee methods are carried out effectively.    
As time progress with the use of this project, a Telephone Initiated Guided Response 
(TIGR) video could be created for patients to watch in their rooms on the television prior to 
discharge.  The paper copies could be made electronic and emailed to patients to provide readily 
available information at their fingertips.  APRNs and nursing staff are encouraged to add 
information to the discharge education material to increase the usefulness to patients and their 
families after discharging.   
Sustainability  
 This project demonstrated a strong commitment to reduce 30-day readmission rates and 
deliver the greatest care to the allogenic stem cell transplant patients at any hospital.  The stem 
cell project was successful in educating patients about preventative measures, common 
complications, and improving post-transplantation care knowledge.  Administration support is an 
important element to the sustainability of any project.  The benefits and the progressive 
outcomes of this mainstay program within the academic facility have been accepted by senior 
stakeholders and staff members.  The administration at this academic facility were vested, 




readmissions in the oncology department.  The bone marrow unit will continue to make the 
discharge protocol the standard of care for allogenic SCT patients.  The PowerPoint presentation 
was made available in the conference room located on the unit to aid in continued staff 
education.   
 This PI released all duties to the nursing leadership in preparation for the longevity of this 
project on the bone marrow unit.  All resources from this project were distributed to each of the 
staff members and leadership members to continue monitoring outcome and process 
measurements.  Over time, practices may change as different guidelines and procedures improve, 
nonetheless the fundamental principles of this stem cell project will remain in place.    
Healthcare Quality Impact. 
 Allogenic SCTs have a massive impact on the lives of transplant patients and their 
families (Bell et al., 2017).  Evidence from the review of literature indicated that SCPs in the 
clinical setting provided a safe practice that was associated with increased patient knowledge of 
preventative measures and improved health outcomes (Seto et al., 2018).  SCPs assigned 
responsibility for managing ongoing post-transplant care and provided the necessary tools to 
support patient engagement in conversations about prevention, follow-up care, and other 
concerns when meeting with their oncology healthcare providers (Selove et al., 2016). The stem 
cell transplant program reduced 30-day readmission rates among allogenic stem cell transplant 
patients while improving patient knowledge and understanding of post-transplantation care.  All 
interventions provided in this project were evidence-based research efforts that provided overall 
quality care and resources to patients suffering with acute myeloid leukemia.  Through the 




discharge home safely with preventative measures at their fingertips to utilize after 
transplantation.   
This project may also help with reducing hospital costs to patients and Medicare by 
improving communication and care coordination in discharge plans and reduce avoidable 
readmissions (Centers for Medicare & Medicaid Services, 2020).   
Policy Implications. 
There were no policies or protocols for the discharge process on the bone marrow unit.  
The implementation of this DNP project assisted with developing a discharge policy that created 
awareness for improving patient education during the discharge process in this healthcare 
system.  This project demonstrated the ability to monitor and evaluate improvements in patient’s 
knowledge of post-transplant care.  Implementing policy changes with this project should be 
considered in this academic facility as patients demonstrated increased knowledge and improved 
health outcomes as there were no 30-day readmissions noted. 
Dissemination 
 The results of this project will be disseminated virtually to the DNP committee at the 
University of Arkansas, Eleanor Mann School of Nursing and the academic facility where this 
project was implemented using a PowerPoint presentation.  The results of this project will be 
shared with the community oncology members interested in providing evidence-based care to the 
leukemic population.   
 Project outcomes will be shared with the local academic facility oncologists, nurse 
practitioners, and registered nursing staff to demonstrate the effectiveness and benefits of using 




provided these healthcare professionals can incorporate key teaching points into their everyday 
practice.   
Professional Reporting. 
 Dissemination via professional reporting will emphasis the importance of this project and 
highlight the positive outcomes of increased knowledge of post-transplantation and decreased 
30-day readmission rates.  Project results will be distributed to the Journal of Oncology, the 
American Journal of Clinical Oncology, and the Journal of Cancer Research & Clinical 
Oncology.  Future endeavors are to provide a PowerPoint presentation at the local level during 
the St. Vincent’s Infirmary Oncology & Chemotherapy trainings for annual certification hours.  
Lastly, the dissemination of these results can be presented in the near future to the Arkansas 
Clinical Oncology Association and Hematology Society and the Arkansas Cancer Summit all 
held annually to showcase recent progress in meeting the goals and objectives of the state’s 
comprehensive cancer plan.   
Conclusion 
This DNP project illustrated the usefulness of a routine discharge program implementing 
SCPs along with a follow-up questionnaire among allogenic SCT patients.  Evidence supported 
the use of routine SCP and follow-up measures to decrease 30-day readmission rates.  The 
implementation of SCPs provided allogenic SCT patients with post-transplantation knowledge of 
preventative measures and post-transplant complications.  Over the 10-week period, this project 
demonstrated patient education on post-transplantation care was a milestone for reducing 30-day 
readmission rates among stem cell transplant patients.  Providing evidence-based educational 
material has shown to significantly increase patient knowledge of preventative measures.  




readmissions, this project demonstrated that both nursing interventions and patient education 
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Appendix A: Global Aims Assignment 
 
Write a Theme for Improvement: The Effects of a Survivorship Care Plan on Hospital Readmission 
Rates in Allogenic Stem-Cell Transplant Patients  
Global Aim Statement 
Create an aim statement that will help keep your focus clear and your work productive: 
 
We aim to decrease readmission rates of allogenic stem-cell patients post transplantation 
(Name the process) 
In: UAMS E7 Bone Marrow Transplant Unit 
(Clinical location in which process is embedded) 
 
The process begins with: implementing survivorship care plans during the discharge process 
                          (Name where the process begins) 
 
The process ends with: with decreasing readmission rates 
(Name the ending point of the process) 
By working on the process, we expect: decrease readmission rates 
                                                                                                                        (List benefits) 
 
It is important to work on this now because: it is a gap in care for post-transplantation complications that 
necessitate readmission within four months post transplantation among allogenic patients 
                                                                                                                   (List imperatives) 
 
Create Flowchart 
Specific Aim Statement 
We will:   improve   increase   decrease 
 
The:   quality of   number/amount of    readmission rates among allogenic patients  
                        (process) 
 
By:  25 percent 




                       (baseline state/number/amount/percentage) 
 
To/By: implementing a survivorship care plan during the discharge process and assess information perceived by patient 
utilizing the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire 25 




















































Key Guide to Process Flowchart 
 
Patient accepted 
















Patient is prepared for 
inpatient hospital stay 







status nurse is 
assigned 
CVL placed by IR & 7 






Patient has to “nadir” 
down and recover count 
to be discharged 
Counts have recovered 
patient experiencing no 
complications ready for 
discharge 
tPatient agrees 
and is ready for 
discharge and has 












































Represents a connection 







































































.   
 
 
30 day readmission were related to 
infectious complication such as GvHD.  
These infectious outcomes led to poor 




















cohort N=23 Metanalysis  CMV infections after SCT is a critical 
complication and can be fatal.  CMV affects 
the liver, lungs, and brain which results in a 


































Metanalysis  Primary care providers who received 
survivorship care plans from an oncologist 
were more likely to report survivorship care 


















































Patient data collected 
from third quarter of 
2010 through third 




participating in the 




based resources  
Data collected from third 
quarter of 2010 through 
third quarter of 2015.   
 
Key data elements included 
estimation of costs, and 
patient living with cancer 





Literature search found that SCPs are 
innovative strategies to promote 
communicative health literacy and engage 




































Data collected via survey 
and found that 54% of 
survivorship commented 
that financial concerns were 
the biggest problem post 
transplantation.   
 
. 
Survivorship care plans are applicable to all 
survivors and can help provide financial 
resources to reduce financial toxicity which 


























N-132 Data was acollected via 
insurance claims and web-
based resouces 
Found that allogenic stem cell transplants 
are among the highest of all transplants.  
This burden leds to many financial 
complications among patients and led to 
lower follow-up appointments.  Also found 
that allogenic patients have a higher overall 







































Based on the information gathered from the 
cancer survivors a new framework was 
designed to implement quality improvement 




























Survies were gathered from 
cancer survivors living with 
complications from GvHD 
Survivorship care plans should be 
recommended to explore and develop to 
help build on patient experiences and 










































N=13 Randomized and non-
randomized studies were 
used to help gather 
information on the effective 
of SCPs in the health care 
delivery system 
Findings from this study found that single 
study had positive correlation with SCPs, 





































Complications post-allogenic transplant can 























N=15 Electronic health records A structured and intense follow-
up process in the first 60 days 
post-transplant may be the most 




















































Data collected between 
January 2011 and June 
2017 via surveys 
 
Written treatment summary and 
follow-up care plans enhances 

























N=29 Randomized study Oncology providers supported 
the use of survivorship care 
plans, but reported significant 

















USA No theory 
applicable 
Readmission

















Data collected by trained 




High risk patients readmissions 
are common.  Enhanced 
education and follow-up through 




































N=29 Electronic health records Survivorship care plans will help 
to improve the design for future 



























N=125 Data was obtained via 
survivor interviews 
 
This study showed that risk 
factors within 100 days of 
discharge did not affect non-









Appendix D: Theoretical Framework 









        
















     
     
     
    
  
Allogenic Stem-Cell Transplant 
Patients are experiencing post-
transplant complications necessitating 
hospital readmission within 2 months 
necessitating hospital readmission 









Implement Survivorship Care 
Plans prior to discharge to 




























Identification of problem 
Gather data for problem 
Determine staff/patient 







Encourage feedback to 
improve care plan 
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Appendix H: Data Collection Sheets 
 
SCP Questionnaire  
 






Value and Label 
Q1 
We are interested in the information you have 
received from the survivorship care plan 
reviewed with you and your family prior to 
discharging home. This packet discussed 
information on preventative measures and 
common complications. Please answer ALL 
questions yourself by circling the choice(s) 
that best answers the question.  The 




If you had a temperature of 100.4 or greater, 
would you? 
Numeric 
1. Notify your doctor immediately or go to 
the nearest emergency department 
2. Take Tylenol and recheck 1 hour later 
3. Use cool compresses to reduce fever 
4. Do nothing because this is normal 
Q3 Which best describes symptoms of infection? Numeric 
1. Temperature of 100.4 or greater 
2. Shaking chills with or without fever 
3. Redness, swelling, or drainage at your 
central line site 
4. All of the above 
Q4 Which best describes infection prevention? Numeric 
1. Handwashing 20-30 seconds regularly 
before eating, after toileting, coughing, 







Value and Label 
2. Being in contact with people who are 
sick and contagious 
3. Only bathing or showering once every 
7 days with antibacterial soap 
4. There is no such thing as infection 
prevention 
Q5 
Which complications are the most common 
after transplantation? 
Numeric 
1. Infection, Cytomegalovirus, and Graft 
versus Host Disease 
2. Hepatitis A, Hepatitis C 
3. Colon cancer and rectal bleeding 
4. Hyperlipidemia and Hypertension  
Q6 
Which of these preventative measures are 
important? 
Numeric 
1. Drinking alcohol heavily with more than 
2 drinks a day 
2. Staying physically active (2.5 hours each 
week with moderate exercise) 
3. Eating an unhealthy diet with plenty of 
fast food. 
4. Sitting on the couch for 8-10 hours a 
day 
Q7 
Which best describes a scenario that should 
be reported to your oncologist? 
Numeric 
1. You should never report any symptoms  
2. Exposure to chickenpox or shingles 
3. A headache that resolved within 2 
hours 
4. An increased appetite  
Q8 
Which best describes common medications 













Value and Label 
Q9 
If your central catheter site becomes painful, 
swollen, or red you should? 
Numeric 
1. Just remain calm the pain will go away 
2. Try to take the dressing off to relieve 
the pain 
3. Call the clinic or your oncologist 
immediately 
4. Take Tylenol this is a normal reaction 
Q10 
This last set of questions gives us information 
about the type of sample we collected.  Thank 
you for your assistance. 
Text  
Q11 







Select the highest level of education you have 
completed. 
Numeric 
1. Less than high school 
2. High school graduate 
3. Some college 
4. 2 year degree 
5. 4 year degree 
6. Masters’ degree 
7. Doctorate or professional degree 
Q13 




2. Black or African American 




Q14 Please enter your age Text  
Q15 What is your household income category? Numeric 
1. $0 - $39,999 
2. $40,000 - $79,999 







Value and Label 
4. $120,000 or more 
 
Are you now married, widowed, divorced, 






















Value and Label 
Q1 
We are interested in the 
information you have received 
about aspects of your disease 
and its treatment, in order to 
improve your health care.  Please 
answer ALL questions yourself 
by circling the number that best 
applies to you.  There are no 
right or wrong answers.  The 
information that you provide will 
remain strictly confidential 
Text  
Q2_1 
The purpose of any medical tests 
you had undergone? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit 
4. Very much 
Q2_2 
The results of the medical tests 
you received? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit 
4. Very much 
Q2_3 
The medical treatment 
(chemotherapy, radiotherapy, or 
surgery)? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit 
4. Very much 
Q2_4 
The possible side-effects of your 
treatment? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit 
4. Very much 
Q2_5 
Tips of managing your illness at 
homes? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit  
4. Very much 
Q3 
Did you receive written 


















Value and Label 
Q5 
Please specify which topics you 
wish to receive more information 
Text  
Q6 






Please specify which topics you 
wish to receive more information 
Text  
Q8 
Overall has the information you 
received been helpful? 
Numeric 
1. Not at all 
2. A little 
3. Quite a bit  
4. Very much 
Q10 
Select the gender identity that 






Select the highest level of 
education you have completed. 
Numeric 
1. Less than high 
school 
2. High school 
graduate 
3. Some college 
4. 2 year degree 
5. 4 year degree 
6. Masters’ degree 




Select the race or ethnicity that 
best represent you 
Numeric 
1. White 
2. Black or African 
American 
3. American Indian 




Q13 Please enter your age Text  
Q14 
What is your household income 
category? 
Numeric 
1. $0 - $39,999 
2. $40,000 - 
$79,999 
3. $80,000 - 
$119,999 










Value and Label 
Q15 
Are you now married, widowed, 












Appendix I: Patient Education Materials 
Blood and Marrow Transplant Survivor Care Plan 
 
Congratulations on your allogenic stem cell transplant.  Thank you for joining the 
Survivorship Care Plan for Allogenic Survivors study.  This packet contains the 
following materials: 
• Your personalized care plan 
• Preventative Measures for Infection 
• Common Complications post-transplantation 
• Common Medications post-transplantation 
• Activities of Daily Living Precautions 
 
This Survivorship Care Plan includes a summary of information relevant to you and is 
important to share with your oncologist and other medical care providers.  Your 
doctor may recommend or order other tests or evaluations on a different schedule 
based on your specific situation.  Follow his or her recommendations carefully.  
Transplant follow-up care is important to protecting your health, even many years 
after transplant.  Your care plan is organized in sections to better assist you with 
understanding each component. 
 
For this study, treatments before your transplant are not included in this survivorship 
care plan, please contact your oncologist for your questions about treatment before 
transplant. 
 






















Blood and Marrow Transplant Survivor Treatment Summary 
 
For: 
Date Your Treatment Summary was Created:  
If you need to go to urgent care or the emergency room, it is helpful 
to take the care plan with you.   
 
Your Medical Information 
 






Date of Diagnosis: 
 
Your Transplant Information 
 
Transplant center name: UAMS E7 & UAMS Winthrop R. Rockefeller Cancer 
Institute 
Address: 4018 W Capitol Ave. Little Rock, AR 72205 
 




Date of Transplant: 
 
Age at Transplant: 
 
Transplant Type:  
 













Recommendations for your Preventative Care 
 
IMMUNE SYSTEM 
o Wear masks out in public places and large crowds 
o Avoid people who are sick or have been recently sick 
o Wash hands frequently 20-30 seconds with antibacterial soap or use alcohol-
based hand sanitizer  
o Vaccines to prevent infections (once cleared by oncologist) 
EYES 
o Wear sunglasses every time you go outside. 
o Vision screening once a year by your eye doctor to check how well you can 
see 
MOUTH 
o Dental exam and teeth cleaning by a dentist at least once a year.   
o Use a soft bristle toothbrush 




o Don’t smoke or use chewing tobacco.  Stay away from second-hand smoke 
HEART AND BLOOD VESSELS 
o Blood pressure should be checked every time you visit the clinic 
o Blood tests to check your cholesterol level at least once a year.  This includes 
triglycerides, LDL, and HDL 
LIVER 
o Liver function blood test at least once a year  
KIDNEYS AND BLADDER 
o Blood pressure should be checked every time you visit the clinic 
o Kidney test at least once a year including testing on protein levels in your 
urine. 
BONES 
o Bone density scan test once a year 
SKIN 
o Do a self-exam of your skin every month to check for any changes (rash, 
unusual growth, or patches) 
o Use sunscreen with SPF 15 or higher every time you go outside.  Reapply at 
least every 2 hours, or more often if you’re sweating or in and out of the 
water 
o Avoid direct sunlight.  Wear a broad-brimmed hat or use a large umbrella to 
protect your skin. 
o Use an electric razor when shaving 
NERVOUS SYSTEM 





o Blood test to check how well your thyroid is working 
o Blood test to assess your sex hormones 
o Fasting glucose (sugar) test to check for diabetes 
GENITALS AND SEXUAL HEALTH 
o Gynecology exam at least once a year for women 
o Discuss with your doctor if you are experiencing sexual side effects such as 
vaginal dryness, pain with sex, or difficulty having an erection 
FERTILITY AND FAMILY PLANNING 
o If you want to have children in the future, ask your doctor to refer you to a 
fertility doctor 
EMOTIONAL HEALTH 
o Going through a transplant is a very emotional experience.  Your feelings 
and needs will change a lot, maybe even every day.  It’s important that you 
talk openly and regularly with your oncologist, family, and friends.  
DIET AND NUTRITION 
o Eat a healthy diet  
o Keep yourself well hydrated 
o Avoid foods with lots of processed (fake) sugar or saturated (bad) fat  
GENERAL HEALTH 
o Use alcohol in moderation (less than 2 drinks a day) 
o Stay physically active (2.5 hours each week of moderate exercise) 
o Avoid people that are sick or contagious 
Central Catheter Line Care 




o Swelling  
o Bleeding 
Call the clinic or your oncologist right away if: 
o You have redness, swelling, or drainage around the area where the catheter 
exists your body 
o Your needless connector falls off 
o You have a temperature of 100.4 or greater 
o You have a break or leak in your catheter 
















• Fever (100.4) 
• Chills & Sweat 
• Shortness of breath 
• Burning or pain with urination 
• Change in cough or a new cough 
• Sore throat or new mouth sore 
 
Cytomegalovirus S/S:  
• Fever (100.4) 
• Sore Throat 
• Fatigue 
• Swollen glands 
Graft versus Host Disease S/S: 
• Rash, raised, or discolored area 
• Yellow discoloration 
• Nausea, vomiting, diarrhea, or 
abdominal pain or abdominal 
swelling 
• Dry eyes or visual changes 
• Dry mouth, white patches inside 
the mouth, pain, or sensitivity 
Interstitial Pneumonitis S/S: 
• Shortness of breath 
• Dry, hacking cough without 
phlegm 
• Extreme tiredness and weakness 
• Decrease or no appetite 
• Unexplained weight loss 
• Mild pain in chest  
• Labored breathing 
Hepatic Sinusoidal Obstruction 
Syndrome 
S/S: 
• Abdominal pain 
• Fluid retention 
• Jaundice 
• Ascites  
• Enlarge liver 
Bleeding  S/S 
• Tiny, purplish-red spots on your 
skin 




• Bleeding from rectal area, gum, or 
nose 
Mucositis S/S: 
• Red, shiny or swollen mouth and 
gums 
• Blood in the mouth 
• Sores in the mouth, gums, or 
tongue 
• Soreness or pain in the mouth or 
throat 
• Difficulty swallowing  
• Feeling of dryness, mild burning, 
or pain 
Nausea & Vomiting S/S: 
• Abdominal pain 
• Lightheadedness 
• Vertigo 
• Rapid pulse 
• Excessive sweating 
• Dry mouth 
Diarrhea S/S: 
• Frequent loose, watery stools 
• Abdominal cramps 
• Abdominal pain 
• Fever 
• Lightheadedness or dizziness  
• Dehydration 
Sexual dysfunction & Infertility S/S: 
• Vaginal dryness 
• Irregular periods or no periods 
• Erectile dysfunction 
• Decreased libido  
• Painful intercourse 






Adapted from UC Davis Medical Center https://secure.ucdmc.ucdavis.edu/cancer/Specialties/stem-
cell-transplant/pdf/SCTdischarge.pdf 
 





Common Medications Used After Transplant 
 
This is a list of common medications used after a transplant to treat infections that can 
occur when the immune system and white blood cell counts are suppressed.  **Your 
oncologist may prescribe other medications depending on your health status.   
 
 
Name Type of Drug Why Used Side effects 
SMX/TMP 
(Bactrim, Septra) 























































Valganciclovir Antiviral Used to treat 
cytomegaloviru







Ganciclovir Antiviral Used to treat 
cytomegaloviru












Immunosuppressive Used to prevent 











Immunosuppressive Used to prevent 










Immunosuppressive Used to prevent 








Immunosuppressive Used to prevent 











Used to prevent 


































The Centers for Diseases Prevention and Control (2000).  
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm  
 




Activities of Daily Living Education 
Discharging Home from the Hospital:  Transplant team members will provide you 
with the information about your post-transplant care.  It is important to ask questions 
and take notes. Some common guidelines regarding discharge planning and home 
care are listed below: 
• General Protection: Wear a mask at all times while in public and visiting the 
hospital property, especially in waiting rooms.  Wash hands for 20-30 seconds 
or use hand sanitizer regularly before eating, after toileting, coughing, 
sneezing, and touching pets 
• A clean home:  Your home should be thoroughly cleaned at least a few days 
before you are discharged due to your risk for infection. Special attention 
should be given to the floors, carpets, bathtubs, sinks and toilets. Have the 
filter on your ventilation system changed to decrease dust and dirt. You are 
not allowed to clean:  Let your family and friends clean for you and please 
stay out of the room they are cleaning. Cleaning should be done on a regular 
basis.  
• Do not share:  Use your own utensils, towels and toothbrush. Clean bath 
towels and linens regularly in HOT water.  
• Plants and Flowers:  Limit the number of plants and flowers in your house. 
DO NOT take care of them. Allow your caregiver to water and re-pot them. 
You should avoid caring for plants and gardening for six months and during 
periods of substantial immunosuppression. Once you are able to garden, you 
must use garden gloves and we recommend wearing a mask.  
• Pets: You can keep your pets in your home, and you CAN pet them. 
Remember to wash your hands afterwards. DO NOT clean litter boxes, bird 
cages, fishbowls, etc. DO NOT handle animal excretions for at least 1-year 
post-transplant 
Infection Prevention: At any time when a stem cell transplant patient develops a 
temperature 100.4 or greater call your oncologist or go to the nearest emergency 
department.  DO NOT take any Aspirin, Acetaminophen (Tylenol), or Nonsteroidal 
Anti-Inflammatory Drugs (NSAIDs) without consulting with your oncologist.   
Infection & Neutropenia: Infection is the most common side effect of 
transplantation. This is due to the destruction of white blood cells (that help 
fight infection) by chemotherapy. Infections can come from the environment, 
but the most common source of infection is bacteria originating from the 
patient’s own body.  It is recommended that allogeneic transplant patients 
follow the guidelines listed below to prevent infection:   
• bathe or shower daily with antibacterial soap  




• cleanse rectal area after each bowel movement  
• avoid contact with people who have colds, flu, chicken pox, or any other 
contagious disease  
• handwashing 20-30 seconds regularly before eating, after toileting, 
coughing, sneezing, and touching pets 
• take antibiotics/antivirals/antifungals as prescribed  
Calling the Transplant Team  
If you do get an infection, your doctor should be notified immediately. The following 
is a list of signs and symptoms that should be reported:  
• A temperature greater than 100.4 degrees F.  
• A persistent cough.  
• Shaking chills with or without fever.  
• Persistent nausea and vomiting.  
• Persistent pain.  
• Diarrhea, constipation or pain with bowel movements.  
• Shortness of breath.  
• Excessive fatigues, irritability, or lethargy.  
• Chills that occur after your central line is flushed.  
• Redness, swelling, drainage, or tenderness at your catheter site.  
• Pain, burning, or increased frequency with urination.  
• Sores in the mouth or throat.  
• Any sore or wound that does not heal.  
• Swelling in any area after injury.  
• Unusual vaginal discharge or itching.  
• Development of a rash on your skin.  
• Presence of blood when vomiting.  
• Blood in your urine or stools (red or black).  
• Persistent nausea, vomiting, constipation, or diarrhea.  
• Exposure to chicken pox.  
• Sudden bruises or hives.  
• Headache that persists or any severe headache.  
• Blurry vision.  
• Persistent dizziness.  
Call 911 in an emergency situation. 
References: The Centers for Diseases Prevention and Control (2000).  
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm 






Appendix J: Needs Assessment Questionnaire with Analysis 
 
Needs Assessment Questionnaire 
 
The purpose of this questionnaire is to gather information regarding the care of patients 
who undergo allogenic stem cell transplantation.  This information will be used to help 
improve patient health outcomes post-transplant once discharged from the hospital.   All of 
the information collected from this survey will be kept confidential.  This questionnaire should 
take approximately 15-20 minutes to complete. 
 
Role: Administration (1), MD (1), CSM (1), APRN (2), RN (4) 
Employment Status: Full time (9) 
 
1. What causes patients to be re-admitted or seen acutely ill following procedures?  
• Uncontrolled Nausea & Vomiting 
• Diarrhea  
• Failure to thrive  
 
2. What are the most common complications experienced by patients readmitted after 
allogenic stem cell transplant?  
• Infection  
• C-Diff  
• Elevated LFTs  
• Graft vs Host Disease 
 
3. What changes can be made to improve patient health outcomes?  
• Frequent Readmissions 
• Inadequate Self Care knowledge  
• Workload demand for RNs 
• Failure to recognize high-risk patients 
• Ineffective discharge planning 
• Lack of resources and education 
 
4. What aspects of the discharge process need to be improved?  
• Preventative Care Measures 
• Personalized Education to patient and family  
• When to seek medical care  
• Transplant knowledge 
 
5. Are allogenic patients are given all the tools needed to be successful at home 
following discharge? If no, explain why.  (Examples: proper education related to 
medications, health, diet, etc.). 
• No reported by 75% of nurses because there is no standardized discharge process 
that provides the necessary materials that patient’s need 





6. Are staff members prepared to make changes in terms of a standardized discharge 
process?  
• Yes reported by 100% staff and stakeholders 
• No  
 
7. Do you feel that management will support ideas to improve the discharge process 
to reduce readmissions?  
• Yes (100%) 
• No (0%) 
 
8. Are you willing to help implement a change using a standardized discharge 
process? 
• Yes (100%) 













Appendix J: Survivorship Care Plan Questionnaire 
 
We are interested in the information you have received from the survivorship care 
plan reviewed with you and your family prior to discharging home.  This packet 
discussed information on preventative measures and common complications.  Please 
answer ALL questions yourself by circling the choice(s) that best answers the 
question.  The information that you provide will remain strictly confidential.  
Demographic information is needed to help with future research. 
 
1. If you had a temperature of 100.4 or greater, would you? 
o Notify your doctor immediately or go to the nearest emergency 
department  
o Take Tylenol and recheck 1 hour later 
o Use cool compresses to reduce fever 
o Do nothing because this is normal 
 
2. Which best describes symptoms of infection? 
o Temperature of 100.4 or greater 
o Shaking chills with or without fever 
o Redness, swelling, or drainage at your central line site 
o All of the above 
 
3. Which best describes infection prevention? 
o Handwashing 20-30 seconds regularly before eating, after toileting, 
coughing, sneezing, and touching pets 
o Being in contact with people who are sick and contagious 
o Only bathing or showering once every 7 days with antibacterial soap 
o There is no such thing as infection prevention 
 
4. Which complications are the most common after transplantation? 
o Infection, Cytomegalovirus, and Graft versus Host Disease 
o Hepatitis A, Hepatitis C 
o Colon cancer and rectal bleeding 
o Hyperlipidemia and Hypertension  
 
5. Which of these preventative measures are important? 
o Drinking alcohol heavily with more than 2 drinks a day 
o Staying physically active (2.5 hours each week with moderate exercise) 
o Eating an unhealthy diet with plenty of fast food. 
o Sitting on the couch for 8-10 hours a day 
 
6. Which best describes a scenario that should be reported to your oncologist? 




o Exposure to chickenpox or shingles 
o A headache that resolved within 2 hours 
o An increased appetite  
 





o All of the above 
 
8. If your central catheter site becomes painful, swollen, or red you should? 
o Just remain calm the pain will go away 
o Try to take the dressing off to relieve the pain 
o Call the clinic or your oncologist immediately 






Appendix K: EORTC-QLQ-INFO25 QUESTIONNAIRE 
We are interested in the information you have received about aspects of your disease and its 
treatment, in order to improve your health care.  Please answer ALL questions yourself by 
circling the number that best applies to you.  There are no right or wrong answers.  The 
information that you provide will remain strictly confidential.   
During your stem cell transplant hospitalization, how much information did you 
received on: 
Not at all      A little      Quite a bit      Very much  
 
1. The purpose of any medical tests you    1  2  3  4 
had undergone? 
 
2. The results of the medical tests you        1  2  3  4 
received? 
 
3. The medical treatment (chemotherapy, 1  2  3  4 
radiotherapy, or surgery)? 
 
4. The possible side-effects          1  2  3  4  
of your treatment?     
          
5. Tips of managing your illness at home?  1  2  3  4 
 
6. Did you receive written information at discharge?         Yes   No 
 
7. Do you wish to receive more information?   Yes  No 




8. Do you wish that you had received less information? Yes   No 
a. If yes, please specify on which topics? 
 
      Not at all      A little      Quite a bit      Very much 
9. Overall has the information you          1                 2     3  4 













Appendix L: Pre-Transplant Script 
 
Hello _________________,  
 
My name is Chantaney Williams and I am a doctoral nurse practitioner student at the University 
of Arkansas.  I am working here at UAMS in Little Rock, AR to begin a survivorship care plan 
program following allogenic stem cell transplantations.  Previously, patients have been 
discharged from the hospital with no additional information given about post-transplantation 
care, but current research indicates survivorship care plans are helpful with follow-up care and 
additional information on ways to reduce coming back to the hospital.   The purpose of this 
project is to decrease 30-day readmissions to the hospital among allogenic stem cell transplant 
patients, allowing you to have information at your fingertips about common complications, 
preventative measures, and decreasing the cost of readmissions from your transplant procedure. 
 
Because you are scheduled for a stem cell transplant, your participation would include a short 
knowledge test prior to discharge and receiving a survivorship care plan prior to going home.  In 
the outpatient oncology clinic, you will receive two questionnaires at your initial visit and then 
one questionnaire once weekly for three weeks.  Your participation would be greatly appreciated 
in efforts to improve our stem cell program.  Your willingness to participate in this project will 
help with future efforts of improving our program for the future.   
 
Would you be willing to participate in this project? 
 
 











Appendix M Discharge Script 
 
Hello _________________,  
 
Please take 10-15 minutes to complete this short SCP Questionnaire that will be used as a tool to 
help with future research to improve the Survivorship Care Plan. This questionnaire is seeking to 
assess your level of knowledge on preventative measures and complications post-transplantation.  
If you have any questions or need clarification, please do not hesitate to ask.   
 
This survivorship care plan consists of information that is pertinent to your allogenic stem cell 
transplant.  This packet can be shared between you and your oncologist to help make decisions 
about your care.  Transplant follow-up care is important to protecting your health.  This packet 
contains your personalized care plan, steps you can take to get the most out of your care plan, 
and how to get your questions answered.  Additional information is provided on preventative 
measures, common complications, and common medications.  Your survivorship care plan is 
organized in sections to better assist you with finding the information needed once discharged.   
 
Please take time review this information again at home and familiarize yourself with tips you can 
use to prevent infections and decrease your chances of being readmitted to the hospital.  If you 
have any questions, please feel free contact the oncology clinic or ask your oncologist.  Thank 
you for participating in the Survivorship Care Plan program.  We hope the efforts of this project 
will serve as a reference point upon your discharge. 
 
 












Appendix N: Consent Form 
 
The Effects of a Survivorship Care Plan on Hospital Readmission Rates in Allogenic Stem 
Cell Transplant Patients  
 
 
PRINCIPAL INVESTIGATOR  
Chantaney Williams  
University of Arkansas Eleanor Mann School of Nursing 





Dr.  Michele Kilmer 
University of Arkansas Eleanor Mann School of Nursing 
606 N.  Razorback Rd. 
1-479-575-3581 
michelekl@uark.edu  
PURPOSE OF PROJECT 
 
You are being asked to take part in a Doctoral Nursing Practice (DNP) project.  Before you 
decide to participate in this project, it is important that you understand why the project is being 
done and what it will involve.  Please read the following information carefully.  Please ask the 
principal investigator if there is anything that is not clear or if you need more information. 
The purpose of this project is to reduce 30-readmission rates among allogenic stem cell 
transplant (SCT) post transplantation by evaluating post-transplantation education via a 
survivorship care plan (SCP) with a survey at two days, one week, two weeks, and three weeks 
after discharge.   
The aim for this project is to utilize survivorship care plans for allogenic stem cell transplant 
patients prior to hospital discharge in order to reduce 30-day readmission rates.  Following 
protocol implementation, this project expects to track readmission rates in efforts to reduce 
readmission rates among allogenic patients by 10% by March 2021.   
 
PROJECT PROCEDURES 
The following is the suggested procedures that will take place:  
• Patient will be complete a survivorship care plan questionnaire prior to discharge 
• Patient will be provided with survivorship materials upon discharge on the common 
complications and preventative measures 
• Patient will participate in weekly follow-up survivorship questionnaires for three weeks 
in the outpatient clinic 




• Data recorded for your medical record will include demographic data, number of 
readmissions, readmission diagnosis, complications within 30 days of discharge, 
interventions implemented to prevent readmission, complications treated, length of stay 
with readmission, the number of attended visits in the outpatient clinic, and the number of 
missed appointments in the outpatient clinic  
RISKS 
There should be very minimal risks for this project however, emotional and psychological strains 
can occur.  There is a low risk of stress and anxiety for yourself and caregiver assuming care 
responsibility at home. 
 
BENEFITS 
Benefits to participating in this project include:  
• Decreasing 30-day readmission rates 
• Prevention of complications post-transplant 
• Increase patient understanding of common complications and preventative measures 
• Decreased cost for patients and hospital associated with 30-day readmissions 
 
CONFIDENTIALITY 
Participation in this study includes gathering information that could identify you and your 
personal health information.  This information will be kept only for the length of the study (six 
months).  After that time, it will be destroyed or de-identified, meaning we will replace your 
identifying information with a code that does not directly identify you.  The principal 
investigator will keep a link that identifies you to your coded information, but this link will be 
kept secure and available only to the principal investigator.  Any information that can identify 
you will remain confidential.   
To assure patient confidentiality, the principal investigator will keep data in a computer that is 
password protected.  Notes, interview transcriptions, and any other identifying participant 
information will be secured in a locked file cabinet in the personal possession of the principal 
investigator.   
Participant data will be kept confidential to the extent allowed by law and University policy.  
The researcher is legally obligated to report specific incidents which include, but may not be 
limited to, incidents of abuse and suicide risk. 
 
CONTACT INFORMATION  
 
If you have questions at any time about this project, or you experience adverse effects as the 
result of participating in this project, you may contact the principal investigator, whose contact 




participant, or if problems arise which you do not feel you can discuss with the Principal 




Your participation in this project is voluntary.  It is your decision whether or not to take part in 
this project.  If you decide to take part in this project, you will be asked to sign a consent form.  
After you sign the consent form, you are still free to withdraw at any time and without giving a 
reason.  Withdrawing from this project will not affect the relationship you have, if any, with the 
principal investigator.  If you withdraw from the project before data collection is completed, your 




I have read and I understand the provided information and have had the opportunity to ask 
questions.  I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason and without cost.  I understand that I will be given a copy of this 
consent form.  I voluntarily agree to take part in this project.   
 
 
























Appendix O: Copy of Approval Letters 
From: no-reply@eortc.be <no-reply@eortc.be> 
Sent: Monday, July 6, 2020 1:22 AM 
To: Chantaney Williams <crw048@uark.edu> 
Subject: Your request for an EORTC-questionnaire Request ID : 68956 
  
 
Dear chantaney williams, 
Thank you for registering on the EORTC Quality of Life Group website. 
Your registration to obtain permission to use our tools has been approved. During the 
registration process you agreed to our terms and conditions regarding the academic use of 
our questionnaires. You can review the terms and conditions here. 
Please find below the links to the requested tools:  
Information Module (INFO25) - English 







Appendix P: Copy of Site’s IRB Approval 
 
 
Institutional Review Board 
4301 West Markham, #636 









PI Name: Williams, Chantaney  
PI Department: ICE NRSL Medical Onc & Transplant  




Project Title: The Effects of a Survivorship Care Plan on Hospital Readmission Rates in 
Allogenic Stem Cell Transplant Patients  
 
NOT HUMAN SUBJECT RESEARCH DETERMINATION  
 
The Institutional Review Board Director or Designee reviewed your material and determined 
that this project is NOT human subject research as defined in 45 CFR 46.102, and therefore 
it does not fall under the jurisdiction of the IRB review process.  
 
Committee Notes/Comments:  
 
• Per the information provided, this is implementation of a care initiative primarily 
intended to improve local patient outcomes (as opposed to primarily intended to 
create generalizable knowledge). As such, this does not meet the definition of human 
subjects research and IRB oversight is not required.  
 
 
Please keep the IRB advised of any changes that may require the project to be re-classified 
as human subject research.  
 
If you have any questions, please contact an IRB administrator at 501-686-5667. 
Click here to access study.  





Appendix Q: Copy of Approval Letters 
Streamlyne Research <production-research@uasys.streamlyne.org> 
Mon 1/11/2021 9:43 AM 
Your Action List has an eDoc(electronic document) that needs your attention:  
 
Document ID:    181610 
Initiator:              System, Notification 
Type:           Add/Modify KcNotificationDocument 
Title:          Protocol 2010293729 is Approved as Exempt 
 
 
To respond to this eDoc:  










































Appendix S. Proposed Gantt Chart 
 
Appendix S: Final Gantt Chart 
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Appendix U: Proposed Flow Chart 
 
 
             
             
             
             
             
             
             
             
             
             































Symbol Name Function 




Admission department notifies 
bed control for room 
assignment 
Room paged out to 
charge nurse and 
the patient is 
assigned  







SCP Questionnaire  
and education material 
given the night before 
planned discharge 
Patient’s admission 





Allogenic Stem Cell 
Transplantation occurs  
Patient experiences nadir 
phase and becomes 
neutropenic 
Await for patient to begin  
engraftment 7-21 post 
transplant 
Engraftment occurs discharge  
planning over the next 2-3 
days 
Discharge occurs the next 
day to a local housing within 
20 minutes of the hospital 
Patient invited to 
participate in project 
w/goals & aims explained 


















Oval Represents a start and 
end point 
 
Arrows Represent a connection 
between two related points 
 
Parallelogram Represents input/out 
 
Square Represents a process 
 




Appendix V: Final 
Allogenic Stem Cell Flow Chart 
Final Process Flow Chart 
 
 
             
             
             
             
             
             
             
             
             
             






























Key Guide to Process Chart 




Admission department notifies 
bed control for room 
assignment 
Room paged out to 
charge nurse and 
the patient is 
assigned  







SCP Questionnaire  
and education 
material given the 
night before 
planned discharge 
Patient attends initial 
outpatient follow up 









Allogenic Stem Cell 
Transplantation occurs  
Patient experiences nadir 
phase and becomes 
neutropenic 
Await for patient to begin  
engraftment 7-21 post 
transplant 
Engraftment occurs discharge  
planning over the next 2-3 
days 
Discharge occurs the next 
day to a local housing within 
20 minutes of the hospital 
SCP Questionnaire  
and EORTC-QLQ 
25 are initiated at 
initial appointment 
by ARPN 
Data collected by principal 
investigator 
Patient invited to 
participate in project 
w/goals & aims explained 











Symbol Name Function 
 
Oval Represents a start and 
end point 
 
Arrows Represent a connection 
between two related points 
 
Parallelogram Represents input/out 
 
Square Represents a process 
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